CN103479963A - Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof - Google Patents
Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof Download PDFInfo
- Publication number
- CN103479963A CN103479963A CN201310369119.1A CN201310369119A CN103479963A CN 103479963 A CN103479963 A CN 103479963A CN 201310369119 A CN201310369119 A CN 201310369119A CN 103479963 A CN103479963 A CN 103479963A
- Authority
- CN
- China
- Prior art keywords
- rhizoma
- radix
- radix notoginseng
- rheumatoid arthritis
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 39
- 239000002775 capsule Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 229940079593 drug Drugs 0.000 claims abstract description 34
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 16
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 16
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 16
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 16
- 241000180649 Panax notoginseng Species 0.000 claims description 59
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 59
- 238000011282 treatment Methods 0.000 claims description 46
- 239000000843 powder Substances 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 229910001868 water Inorganic materials 0.000 claims description 32
- 238000009835 boiling Methods 0.000 claims description 13
- 239000007902 hard capsule Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 238000002791 soaking Methods 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 7
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000019634 flavors Nutrition 0.000 claims description 7
- 238000012856 packing Methods 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 77
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 14
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 9
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 8
- 241000753128 Periploca <moth> Species 0.000 abstract description 3
- 241000270273 Ptyas dhumnades Species 0.000 abstract description 3
- 235000011477 liquorice Nutrition 0.000 abstract description 2
- 241000725145 Homalomena Species 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 54
- 238000000034 method Methods 0.000 description 34
- INYYVPJSBIVGPH-UHFFFAOYSA-N 14-episinomenine Natural products C1CN(C)C2CC3=CC=C(OC)C(O)=C3C31C2C=C(OC)C(=O)C3 INYYVPJSBIVGPH-UHFFFAOYSA-N 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 30
- INYYVPJSBIVGPH-QHRIQVFBSA-N Sinomenine Chemical compound C([C@@H]1N(CC2)C)C3=CC=C(OC)C(O)=C3[C@@]32[C@@H]1C=C(OC)C(=O)C3 INYYVPJSBIVGPH-QHRIQVFBSA-N 0.000 description 30
- RARWEROUOQPTCJ-RBUKOAKNSA-N cepharamine Natural products C1CC2=CC=C(OC)C(O)=C2[C@@]2(CCN3C)[C@]13C=C(OC)C(=O)C2 RARWEROUOQPTCJ-RBUKOAKNSA-N 0.000 description 30
- 229930002966 sinomenine Natural products 0.000 description 30
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 29
- 239000000284 extract Substances 0.000 description 29
- 230000002401 inhibitory effect Effects 0.000 description 29
- 210000000988 bone and bone Anatomy 0.000 description 27
- 239000000047 product Substances 0.000 description 23
- 208000002193 Pain Diseases 0.000 description 22
- 210000004185 liver Anatomy 0.000 description 21
- 239000012567 medical material Substances 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 230000036407 pain Effects 0.000 description 20
- 238000011160 research Methods 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 210000003734 kidney Anatomy 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 238000005728 strengthening Methods 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- -1 cupreol Chemical class 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 238000001035 drying Methods 0.000 description 14
- 229930182470 glycoside Natural products 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 230000000144 pharmacologic effect Effects 0.000 description 14
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
- 229940109262 curcumin Drugs 0.000 description 13
- 235000012754 curcumin Nutrition 0.000 description 13
- 239000004148 curcumin Substances 0.000 description 13
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 13
- 229960004949 glycyrrhizic acid Drugs 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 12
- 235000019410 glycyrrhizin Nutrition 0.000 description 12
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 108010074051 C-Reactive Protein Proteins 0.000 description 11
- 102100032752 C-reactive protein Human genes 0.000 description 11
- 102100040247 Tumor necrosis factor Human genes 0.000 description 11
- 230000003110 anti-inflammatory effect Effects 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 238000003304 gavage Methods 0.000 description 11
- 210000002216 heart Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 208000006820 Arthralgia Diseases 0.000 description 10
- 206010053615 Thermal burn Diseases 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 239000000341 volatile oil Substances 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 229930182478 glucoside Natural products 0.000 description 8
- 150000008131 glucosides Chemical class 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 229940100601 interleukin-6 Drugs 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 238000004062 sedimentation Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 7
- 108091006146 Channels Proteins 0.000 description 7
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 7
- 239000004378 Glycyrrhizin Substances 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 239000003513 alkali Substances 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 239000000306 component Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 229960003720 enoxolone Drugs 0.000 description 7
- 150000002338 glycosides Chemical class 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 231100000614 poison Toxicity 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 102000003896 Myeloperoxidases Human genes 0.000 description 6
- 108090000235 Myeloperoxidases Proteins 0.000 description 6
- RHBOHEXDGUVIIY-WHOFXGATSA-N Procurcumenol Chemical compound CC1=CC(=O)C(=C(C)C)C[C@@H]2[C@](O)(C)CC[C@H]21 RHBOHEXDGUVIIY-WHOFXGATSA-N 0.000 description 6
- 241001643409 Sinomenium acutum Species 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 230000002490 cerebral effect Effects 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229960005181 morphine Drugs 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- 235000017709 saponins Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000003809 water extraction Methods 0.000 description 6
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 5
- 241000345998 Calamus manan Species 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 5
- 102000002734 Collagen Type VI Human genes 0.000 description 5
- 108010043741 Collagen Type VI Proteins 0.000 description 5
- 244000163122 Curcuma domestica Species 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000036592 analgesia Effects 0.000 description 5
- 230000008485 antagonism Effects 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 206010008118 cerebral infarction Diseases 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000001685 glycyrrhizic acid Substances 0.000 description 5
- 210000004247 hand Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 235000012950 rattan cane Nutrition 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 235000017443 Hedysarum boreale Nutrition 0.000 description 4
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 description 4
- 102000003815 Interleukin-11 Human genes 0.000 description 4
- 108090000177 Interleukin-11 Proteins 0.000 description 4
- 102100030703 Interleukin-22 Human genes 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000002481 ethanol extraction Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 210000004024 hepatic stellate cell Anatomy 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical group CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 229940074383 interleukin-11 Drugs 0.000 description 4
- 108010074109 interleukin-22 Proteins 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 239000000401 methanolic extract Substances 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- 231100000862 numbness Toxicity 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 230000007096 poisonous effect Effects 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000004576 sand Substances 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 3
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 235000014375 Curcuma Nutrition 0.000 description 3
- 239000010282 Emodin Substances 0.000 description 3
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 3
- RHBOHEXDGUVIIY-UHFFFAOYSA-N Epiprocurcumenol Natural products CC1=CC(=O)C(=C(C)C)CC2C(O)(C)CCC21 RHBOHEXDGUVIIY-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000009386 Experimental Arthritis Diseases 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 241000202807 Glycyrrhiza Species 0.000 description 3
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 3
- 241000123866 Homalomena occulta Species 0.000 description 3
- 206010023232 Joint swelling Diseases 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 229930194248 Licoflavone Natural products 0.000 description 3
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- FSLPMRQHCOLESF-UHFFFAOYSA-N alpha-amyrenol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C FSLPMRQHCOLESF-UHFFFAOYSA-N 0.000 description 3
- XOCANRBEOZQNAQ-KBPBESRZSA-N alpha-turmerone Natural products O=C(/C=C(\C)/C)C[C@H](C)[C@H]1C=CC(C)=CC1 XOCANRBEOZQNAQ-KBPBESRZSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 3
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 description 3
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 description 3
- PDNLMONKODEGSE-UHFFFAOYSA-N beta-amyrin acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC23C)C1(C)C PDNLMONKODEGSE-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 230000001964 calcium overload Effects 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000003373 curcuma longa Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 3
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 230000007365 immunoregulation Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- GBRZTUJCDFSIHM-KRWDZBQOSA-N licoricidin Chemical compound C1([C@@H]2COC=3C=C(O)C(CC=C(C)C)=C(C=3C2)OC)=CC=C(O)C(CC=C(C)C)=C1O GBRZTUJCDFSIHM-KRWDZBQOSA-N 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000000811 metacarpophalangeal joint Anatomy 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 3
- 229960004127 naloxone Drugs 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 210000003024 peritoneal macrophage Anatomy 0.000 description 3
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 3
- 238000011020 pilot scale process Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 2
- FSKPDOZBWMKQBY-INIZCTEOSA-N (13as)-2,10,11-trimethoxy-6,8,13,13a-tetrahydro-5h-isoquinolino[2,1-b]isoquinolin-3-ol Chemical compound C1C2=CC(OC)=C(OC)C=C2CN2[C@@H]1C(C=C(C(=C1)O)OC)=C1CC2 FSKPDOZBWMKQBY-INIZCTEOSA-N 0.000 description 2
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 2
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- XQINTCORIZHGFD-UHFFFAOYSA-O 1,2,10-trimethoxy-6,6-dimethyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-6-ium-11-ol Chemical compound C1=C(OC)C(OC)=C2C3=C(O)C(OC)=CC=C3CC3[N+](C)(C)CCC1=C23 XQINTCORIZHGFD-UHFFFAOYSA-O 0.000 description 2
- MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- HZQODNRPUJAVLV-ZSAUSMIDSA-N 1beta,4beta,7alpha-trihydroxyeudesmane Chemical compound O[C@H]1[C@@]2(C)[C@H]([C@](O)(C)CC1)C[C@](O)(C(C)C)CC2 HZQODNRPUJAVLV-ZSAUSMIDSA-N 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 2
- FAMPSKZZVDUYOS-UHFFFAOYSA-N 2,6,6,9-tetramethylcycloundeca-1,4,8-triene Chemical compound CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- KWBPKUMWVXUSCA-AXQDKOMKSA-N 3-[(3s,5s,8r,9s,10r,13r,14s,17r)-5,14-dihydroxy-3-[(2r,4s,5r,6r)-4-methoxy-6-methyl-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] Chemical compound C1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@@H](C[C@@]5(O)CC[C@H]4[C@@]3(O)CC2)O[C@H]2C[C@@H]([C@@H]([C@@H](C)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)OC)=CC(=O)OC1 KWBPKUMWVXUSCA-AXQDKOMKSA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241000208327 Apocynaceae Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241001148495 Cibotium barometz Species 0.000 description 2
- 241000270292 Colubridae Species 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- QRMPRVXWPCLVNI-UHFFFAOYSA-N Curcumenol Natural products C1C(=C)C2CCC(C)C22CC(C(C)C)C1(O)O2 QRMPRVXWPCLVNI-UHFFFAOYSA-N 0.000 description 2
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 2
- QRMPRVXWPCLVNI-YYFQZIEXSA-N Curcumol Chemical compound C1C(=C)[C@@H]2CC[C@H](C)[C@@]22C[C@@H](C(C)C)[C@]1(O)O2 QRMPRVXWPCLVNI-YYFQZIEXSA-N 0.000 description 2
- MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- JBGSWIBJAGBGOP-UHFFFAOYSA-N Dehydronuciferine Chemical compound C1=CC=C2C3=C(OC)C(OC)=CC(CCN4C)=C3C4=CC2=C1 JBGSWIBJAGBGOP-UHFFFAOYSA-N 0.000 description 2
- 241000195958 Dicksoniaceae Species 0.000 description 2
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241001278898 Glycyrrhiza inflata Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- CKIYSMRPIBQTHQ-JKSUJKDBSA-N Michelalbine Chemical compound C12=CC=CC=C2[C@@H](O)[C@@H]2C3=C1C(OCO1)=C1C=C3CCN2 CKIYSMRPIBQTHQ-JKSUJKDBSA-N 0.000 description 2
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 2
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 244000236658 Paeonia lactiflora Species 0.000 description 2
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 241000208343 Panax Species 0.000 description 2
- 241001406327 Periploca sepium Species 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 241000218201 Ranunculaceae Species 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 102100023132 Transcription factor Jun Human genes 0.000 description 2
- FZPYMZUVXJUAQA-UHFFFAOYSA-N Turmerone Natural products CC(C)=CC(=O)CC(C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-UHFFFAOYSA-N 0.000 description 2
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- QJPCKAJTLHDNCS-UHFFFAOYSA-N alloperiplogenin Natural products CC12CCC(C3(CCC(O)CC3(O)CC3)C)C3C1(O)CCC2C1=CC(=O)OC1 QJPCKAJTLHDNCS-UHFFFAOYSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- ZHKVKULEJZXSLW-KZZGZOJNSA-N beta-daucosterol Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(O)[C@H]3CC[C@]12C)O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C ZHKVKULEJZXSLW-KZZGZOJNSA-N 0.000 description 2
- PJWPOUFMMWFJOL-UHFFFAOYSA-N beta-sitosterol-beta-D-glucoside Natural products CCC(CCC(C)C1CCC2C3C=CC4CC(CCC4(C)C3CCC12C)OC5OC(CO)C(O)C(O)C5O)C(C)C PJWPOUFMMWFJOL-UHFFFAOYSA-N 0.000 description 2
- OOWSNEKQIRVGCG-UHFFFAOYSA-N bianfugenine Chemical compound C1=NC(C2=CC=C(C=C2C2=O)OC)=C3C2=C(OC)C(OC)=C(OC)C3=C1 OOWSNEKQIRVGCG-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 2
- 229940036350 bisabolol Drugs 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- JQHTXZNYHSCIFE-FPVZYODXSA-N bullatantriol Chemical compound C[C@]1([C@@H](CC[C@@]2(O)C)O)[C@H]2[C@@H](CC(C)(O)C)CC1 JQHTXZNYHSCIFE-FPVZYODXSA-N 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- BWRHOYDPVJPXMF-UHFFFAOYSA-N carane Chemical compound C1C(C)CCC2C(C)(C)C12 BWRHOYDPVJPXMF-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 230000003177 cardiotonic effect Effects 0.000 description 2
- 210000003797 carpal joint Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- BOLQJTPHPSDZHR-UHFFFAOYSA-N dihydroferulic acid Chemical compound COC1=CC(CCC(O)=O)=CC=C1O BOLQJTPHPSDZHR-UHFFFAOYSA-N 0.000 description 2
- 210000003027 ear inner Anatomy 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- FPJQGFLUORYYPE-UHFFFAOYSA-N epiberberine Chemical compound C1=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C2OCOC2=C1 FPJQGFLUORYYPE-UHFFFAOYSA-N 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 2
- YNWXJFQOCHMPCK-LXGDFETPSA-N isoliquiritin Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-LXGDFETPSA-N 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229930003658 monoterpene Natural products 0.000 description 2
- 235000002577 monoterpenes Nutrition 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229930186642 periplocoside Natural products 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000013930 proline Nutrition 0.000 description 2
- 229930190987 pterosin Natural products 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- GVTRUVGBZQJVTF-YJYMSZOUSA-N salutaridine Chemical compound C1C2=CC=C(OC)C(O)=C2[C@]23C=C(OC)C(=O)C=C3[C@@H]1N(C)CC2 GVTRUVGBZQJVTF-YJYMSZOUSA-N 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 229930004725 sesquiterpene Natural products 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- BENXORZPKXUGMY-UHFFFAOYSA-O stepharanine Chemical compound OC1=CC=C2C=C(C3=C(C=C(C(=C3)O)OC)CC3)[N+]3=CC2=C1OC BENXORZPKXUGMY-UHFFFAOYSA-O 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 229930182493 triterpene saponin Natural products 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- OZQAPQSEYFAMCY-QLFBSQMISA-N α-selinene Chemical compound C1CC=C(C)[C@@H]2C[C@H](C(=C)C)CC[C@]21C OZQAPQSEYFAMCY-QLFBSQMISA-N 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- YKFLAYDHMOASIY-UHFFFAOYSA-N γ-terpinene Chemical compound CC(C)C1=CCC(C)=CC1 YKFLAYDHMOASIY-UHFFFAOYSA-N 0.000 description 2
- DWGVRYKQVZGSIB-UHFFFAOYSA-N (+)-(4S,5S)-germacrone-4,5-epoxide Natural products C1CC=C(C)CC(=O)C(=C(C)C)CC2OC21C DWGVRYKQVZGSIB-UHFFFAOYSA-N 0.000 description 1
- KDPFMRXIVDLQKX-ISGXEFFDSA-N (+)-Curdione Natural products CC(C)[C@@H]1CC(=O)[C@@H](C)CC\C=C(C)/CC1=O KDPFMRXIVDLQKX-ISGXEFFDSA-N 0.000 description 1
- DWGVRYKQVZGSIB-NCKTXVJMSA-N (+)-Germacrone-4,5-epoxide Natural products C1C\C=C(C)\CC(=O)C(=C(C)C)C[C@@H]2O[C@]21C DWGVRYKQVZGSIB-NCKTXVJMSA-N 0.000 description 1
- OGJKMZVUJJYWKO-CYBMUJFWSA-N (+)-Stepharine Natural products C([C@H]1NCCC=2C=C(C(=C3C=21)OC)OC)C13C=CC(=O)C=C1 OGJKMZVUJJYWKO-CYBMUJFWSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 229930013915 (+)-catechin Natural products 0.000 description 1
- 235000007219 (+)-catechin Nutrition 0.000 description 1
- FUCYIEXQVQJBKY-ZFWWWQNUSA-N (+)-δ-Cadinene Chemical compound C1CC(C)=C[C@H]2[C@H](C(C)C)CCC(C)=C21 FUCYIEXQVQJBKY-ZFWWWQNUSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- DHUDRGOPTAAHRB-ARSDKDGVSA-N (-)-homalomenol C Chemical compound CC(C)[C@H]1CC[C@@]2(C)[C@@H]1[C@H]1O[C@]2(O)CC[C@@]1(C)O DHUDRGOPTAAHRB-ARSDKDGVSA-N 0.000 description 1
- FFDULTAFAQRACT-NYYYOYJKSA-N (-)-syringaresinol O,O'-bis(beta-D-glucoside) Chemical compound COC1=CC([C@H]2[C@H]3[C@H]([C@@H](OC3)C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C(OC)C=3)CO2)=CC(OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FFDULTAFAQRACT-NYYYOYJKSA-N 0.000 description 1
- LHYHMMRYTDARSZ-VXGQWTEUSA-N (1r,4s)-1,6-dimethyl-4-propan-2-yl-3,4,4a,7,8,8a-hexahydro-2h-naphthalen-1-ol Chemical group C1CC(C)=CC2[C@H](C(C)C)CC[C@@](C)(O)C21 LHYHMMRYTDARSZ-VXGQWTEUSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- RYHZSFNAGFOCEZ-PYXKSNNZSA-N (2r,3r,4s,5s,6r)-4-[(3r,4s,5s,6r)-6-[[(2r,3r,4s,5s,6r)-4-[(2s,3r,4s,5r,6r)-6-[[(2r,3r,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-[(3r,4s,5r,6r)-6-[[(2r,3 Chemical compound O[C@@H]1[C@@H](O)[C@H](CO)O[C@H]1OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC[C@@H]3[C@@H]([C@H](OC4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@H]5[C@@H]([C@@H](O[C@H]6[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@H]7[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O7)O)O6)O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)C(O[C@H]4[C@H]([C@@H](CO)O[C@@H](O)[C@@H]4O)O)O3)O)O[C@H](CO)[C@@H]2O)O)O1 RYHZSFNAGFOCEZ-PYXKSNNZSA-N 0.000 description 1
- NAJPAGUETSZHOG-DOLQZWNJSA-N (2r,3s,4r,5r)-2-butoxy-2-(hydroxymethyl)oxane-3,4,5-triol Chemical compound CCCCO[C@]1(CO)OC[C@@H](O)[C@@H](O)[C@@H]1O NAJPAGUETSZHOG-DOLQZWNJSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- DWGVRYKQVZGSIB-ZRDDCUNGSA-N (4S,5S)-(+)-Germacrone 4,5-epoxide Chemical compound C1C\C=C(C)/CC(=O)C(=C(C)C)C[C@@H]2O[C@]21C DWGVRYKQVZGSIB-ZRDDCUNGSA-N 0.000 description 1
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- ZDVDVLRYVOZWMP-AWEZNQCLSA-O (6as)-2,10-dimethoxy-6,6-dimethyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-6-ium-1,9-diol Chemical compound C1=C(OC)C(O)=C2C(C=C(C(=C3)O)OC)=C3C[C@@H]3[N+](C)(C)CCC1=C23 ZDVDVLRYVOZWMP-AWEZNQCLSA-O 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- YLRXAIKMLINXQY-ZDUSSCGKSA-O (S)-magnoflorine Chemical compound C1=C(OC)C(O)=C2C3=C(O)C(OC)=CC=C3C[C@@H]3[N+](C)(C)CCC1=C23 YLRXAIKMLINXQY-ZDUSSCGKSA-O 0.000 description 1
- NIZFPXZQERMCLE-KVFWHIKKSA-N (e)-1-[4-[(2s,3r,4s,5s,6r)-3-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxyphenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O[C@H]1[C@@H]([C@@](O)(CO)CO1)O)O)CO)C(C=C1O)=CC=C1C(=O)\C=C\C1=CC=C(O)C=C1 NIZFPXZQERMCLE-KVFWHIKKSA-N 0.000 description 1
- KTRRXJQAOOYSDA-UHFFFAOYSA-N 1,7-bis(4-hydroxyphenyl)heptane-3,5-dione Chemical compound C1=CC(O)=CC=C1CCC(=O)CC(=O)CCC1=CC=C(O)C=C1 KTRRXJQAOOYSDA-UHFFFAOYSA-N 0.000 description 1
- WLXJHVQYKOJBBN-NJVJYBDUSA-N 1-[(1s,3ar,4r,7s,7as)-4-hydroxy-4-methyl-7-propan-2-yl-1,2,3,3a,5,6,7,7a-octahydroinden-1-yl]ethanone Chemical compound CC(C)[C@@H]1CC[C@@](C)(O)[C@@H]2CC[C@H](C(C)=O)[C@@H]12 WLXJHVQYKOJBBN-NJVJYBDUSA-N 0.000 description 1
- UVIVWIFUPKGWGF-UHFFFAOYSA-N 1-o-butyl 2-o-(2-methylpropyl) benzene-1,2-dicarboxylate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCC(C)C UVIVWIFUPKGWGF-UHFFFAOYSA-N 0.000 description 1
- MZLKNWMNBXHXMA-UHFFFAOYSA-N 1-phenylheptylbenzene Chemical compound C=1C=CC=CC=1C(CCCCCC)C1=CC=CC=C1 MZLKNWMNBXHXMA-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HZQODNRPUJAVLV-UHFFFAOYSA-N 1beta,4beta,7alpha-eudesmanetriol Natural products OC1CCC(C)(O)C2CC(C(C)C)(O)CCC21C HZQODNRPUJAVLV-UHFFFAOYSA-N 0.000 description 1
- ADVGKWPZRIDURE-UHFFFAOYSA-N 2'-Hydroxyacetanilide Chemical compound CC(=O)NC1=CC=CC=C1O ADVGKWPZRIDURE-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- QVKQQLYSTODTJN-UHFFFAOYSA-N 2-amino-2-(3-oxo-1,2-oxazol-5-yl)acetic acid;hydrate Chemical compound O.OC(=O)C(N)C1=CC(=O)NO1 QVKQQLYSTODTJN-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- QJPCKAJTLHDNCS-FBAXFMHRSA-N 3-[(3s,5s,8r,9s,10r,13r,14s,17r)-3,5,14-trihydroxy-10,13-dimethyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2h-furan-5-one Chemical compound C1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@@]5(O)CC4)C)CC[C@@]32C)=CC(=O)OC1 QJPCKAJTLHDNCS-FBAXFMHRSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- WRYLYDPHFGVWKC-SNVBAGLBSA-N 4-Terpineol Natural products CC(C)[C@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-SNVBAGLBSA-N 0.000 description 1
- LTVBTVOAUQJJEV-UHFFFAOYSA-N 4-methylindeno[1,2-b]pyridin-5-one Chemical compound C12=CC=CC=C2C(=O)C2=C1N=CC=C2C LTVBTVOAUQJJEV-UHFFFAOYSA-N 0.000 description 1
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 1
- SMRPGWBDLOQHOS-UHFFFAOYSA-N 5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[[9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]oxane-2-carboxylic acid Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4=O)C)(C)CC3)(C)CC2)(C)CO)OC(CO)C(O)C1O SMRPGWBDLOQHOS-UHFFFAOYSA-N 0.000 description 1
- NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 description 1
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- QQUHMASGPODSIW-UHFFFAOYSA-N Albiflorin Natural products C=1C=CC=CC=1C(=O)OCC12C(=O)OC3(C)CC(O)C1CC32OC1OC(CO)C(O)C(O)C1O QQUHMASGPODSIW-UHFFFAOYSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- JQHTXZNYHSCIFE-UHFFFAOYSA-N Bullatantriol Natural products CC1(O)CCC(O)C2(C)C1C(CC(C)(O)C)CC2 JQHTXZNYHSCIFE-UHFFFAOYSA-N 0.000 description 1
- FFSJITPWJCNADF-UHFFFAOYSA-N CCCCCCCCCCCCCCCC[O] Chemical compound CCCCCCCCCCCCCCCC[O] FFSJITPWJCNADF-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 240000007436 Cananga odorata Species 0.000 description 1
- 235000007571 Cananga odorata Nutrition 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000272205 Columba livia Species 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- TYYDXNISHGVDGA-UHFFFAOYSA-N Corotoxigenin Natural products CC12CCC3C(CCC4CC(O)CCC34C=O)C1CCC2C5=CC(=O)OC5 TYYDXNISHGVDGA-UHFFFAOYSA-N 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229930153442 Curcuminoid Natural products 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- ISOIDIYKQYJGMC-UHFFFAOYSA-N D-delta-Cadinol Natural products C1CC(C)(O)CC2C(C(C)C)CC=C(C)C21 ISOIDIYKQYJGMC-UHFFFAOYSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- AXVVWZONCVUAPP-QULPKBGFSA-N Disinomenine Chemical compound C([C@@H]1[C@@H](N(CC2)C)C3)=C(OC)C(=O)C[C@]21C1=C3C(C2=C3C[C@H]4[C@H]5C=C(C(C[C@@]5(CCN4C)C3=C(O)C(OC)=C2)=O)OC)=CC(OC)=C1O AXVVWZONCVUAPP-QULPKBGFSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 206010016173 Fall Diseases 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- KLFIUQCKSSAFFU-QHOIGUMUSA-N Galloylpaeoniflorin Natural products O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@]23[C@]4(COC(=O)c5ccccc5)[C@@H]5O[C@@]2(C)C[C@@](O)(O5)[C@@H]4C3)O1)c1cc(O)c(O)c(O)c1 KLFIUQCKSSAFFU-QHOIGUMUSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- MGAZMNWJFPAAIU-NUFRDJDGSA-N Garryfoline Natural products O[C@@H]1C(=C)[C@H]2C[C@@]31[C@H]([C@@]14[C@@H]5OCCN5C[C@@](C)([C@H]1CC3)CCC4)CC2 MGAZMNWJFPAAIU-NUFRDJDGSA-N 0.000 description 1
- KDPFMRXIVDLQKX-NHFJXKHHSA-N Germacr-1(10)-ene-5,8-dione Chemical compound CC(C)[C@@H]1CC(=O)[C@@H](C)CC\C=C(C)\CC1=O KDPFMRXIVDLQKX-NHFJXKHHSA-N 0.000 description 1
- UZIOUZHBUYLDHW-MSJHMJQNSA-N Ginsenoside Rf Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@@H](O)C2)[C@@H]([C@@](O)(CC/C=C(\C)/C)C)CC3)C1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 UZIOUZHBUYLDHW-MSJHMJQNSA-N 0.000 description 1
- 229920000296 Glucogallin Polymers 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- MKDSBDQLSLPNOQ-YDJDNKAXSA-N Glyuranolide Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@@](CC[C@]4(C)[C@H]5C[C@@]6(C[C@H]4OC6=O)C)(C(=O)OC)C5=CC(=O)[C@@H]3[C@]21C MKDSBDQLSLPNOQ-YDJDNKAXSA-N 0.000 description 1
- MKDSBDQLSLPNOQ-UHFFFAOYSA-N Glyuranolide Natural products C1CC(O)C(C)(C)C2CCC3(C)C(CCC4(C)C5CC6(CC4OC6=O)C)(C(=O)OC)C5=CC(=O)C3C21C MKDSBDQLSLPNOQ-UHFFFAOYSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010056328 Hepatic ischaemia Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101001023770 Homo sapiens Transcription factor NF-E2 45 kDa subunit Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- BCXBIONYYJCSDF-CIUDSAMLSA-N Ile-Val Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O BCXBIONYYJCSDF-CIUDSAMLSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- YNWXJFQOCHMPCK-UHFFFAOYSA-N Isoliquiritin Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-UHFFFAOYSA-N 0.000 description 1
- OWDQPILTDJLGCN-QHRIQVFBSA-N Isosinomenine Chemical compound C1C2=CC=C(OC)C(O)=C2[C@@]23C=C(OC)C(=O)C[C@@H]3[C@H]1N(C)CC2 OWDQPILTDJLGCN-QHRIQVFBSA-N 0.000 description 1
- 102000008986 Janus Human genes 0.000 description 1
- 108050000950 Janus Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- MVAUGMLUJKTORM-UHFFFAOYSA-N Licoricidin Natural products COc1cc2OCC(Cc2cc1CC=C(C)C)c3ccc(O)c(CC=C(C)C)c3O MVAUGMLUJKTORM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108060003100 Magainin Proteins 0.000 description 1
- KYEAXNAYHSCLMT-CVVGWEDFSA-N Magnoflorine Natural products C[C@H]1OC=C2[C@@H]3[C@@H]1CN4CCc5c([nH]c6ccccc56)[C@@H]4[C@@H]3OC2=O KYEAXNAYHSCLMT-CVVGWEDFSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- BJJRDCBDIOEIKD-UHFFFAOYSA-N N-demethyl-sinomenine Natural products C1CNC2CC3=CC=C(OC)C(O)=C3C31C2C=C(OC)C(=O)C3 BJJRDCBDIOEIKD-UHFFFAOYSA-N 0.000 description 1
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 1
- 101710083073 NF-kappa-B inhibitor alpha Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- XQWFHGOIUZFQPJ-USTPAGJBSA-N Neoisoliquiritigenin Natural products O=C(/C=C/c1ccc(O)cc1)c1c(O)cc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O2)cc1 XQWFHGOIUZFQPJ-USTPAGJBSA-N 0.000 description 1
- XQWFHGOIUZFQPJ-LXGDFETPSA-N Neoisoliquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1O)=CC=C1C(=O)\C=C\C1=CC=C(O)C=C1 XQWFHGOIUZFQPJ-LXGDFETPSA-N 0.000 description 1
- XQWFHGOIUZFQPJ-UHFFFAOYSA-N Neoisoliquiritin Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1O)=CC=C1C(=O)C=CC1=CC=C(O)C=C1 XQWFHGOIUZFQPJ-UHFFFAOYSA-N 0.000 description 1
- HJBUYKZTEBZNSH-ZRWXNEIDSA-N Neoliquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C(=O)C[C@H](O2)C=3C=CC(O)=CC=3)C2=C1 HJBUYKZTEBZNSH-ZRWXNEIDSA-N 0.000 description 1
- HJBUYKZTEBZNSH-ONJCETCRSA-N Neoliquiritin Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C(=O)C[C@@H](O2)C=3C=CC(O)=CC=3)C2=C1 HJBUYKZTEBZNSH-ONJCETCRSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- CKIYSMRPIBQTHQ-UHFFFAOYSA-N Noroliveroline Natural products C12=CC=CC=C2C(O)C2C3=C1C(OCO1)=C1C=C3CCN2 CKIYSMRPIBQTHQ-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- MGJLSBDCWOSMHL-WFMNFSIZSA-N Ononin Natural products O(C)c1ccc(C=2C(=O)c3c(OC=2)cc(O[C@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O2)cc3)cc1 MGJLSBDCWOSMHL-WFMNFSIZSA-N 0.000 description 1
- NHVPAQUFIGPNEZ-YJNKXOJESA-N Oplodiol Natural products CC(C)C1=CC[C@H]2[C@H](O)CC[C@](C)(O)[C@]2(C)C1 NHVPAQUFIGPNEZ-YJNKXOJESA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 241000219506 Phytolacca Species 0.000 description 1
- 240000007509 Phytolacca dioica Species 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102100027584 Protein c-Fos Human genes 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- UVPBNPUZWAOBQX-UHFFFAOYSA-N Sarotanoside Natural products OC1C(O)C(O)C(C)OC1OC1C(OC=2C=C3OC(CC(=O)C3=C(O)C=2)C=2C=CC=CC=2)OC(CO)C(O)C1O UVPBNPUZWAOBQX-UHFFFAOYSA-N 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- HSRVPBCIHAXZJD-UHFFFAOYSA-N Sinomendine Natural products C1=NC(C(C)(O)C=2C3=CC=C(C=2OC)OC)=C2C3=CC=C(OC)C2=C1 HSRVPBCIHAXZJD-UHFFFAOYSA-N 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- FZPYMZUVXJUAQA-ZDUSSCGKSA-N Turmerone Chemical compound CC(C)=CC(=O)C[C@H](C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-ZDUSSCGKSA-N 0.000 description 1
- RIARKSMMKCXBML-MTKVKGGCSA-N Uralenolide Chemical compound C([C@]1(C)[C@H]2C=CC3=C4C5)C[C@H](O)[C@](C)(CO)[C@@H]1CC[C@@]2(C)[C@]3(C)CC[C@@]4(C)[C@@H]1C[C@@]5(C)C(=O)O1 RIARKSMMKCXBML-MTKVKGGCSA-N 0.000 description 1
- RIARKSMMKCXBML-UHFFFAOYSA-N Uralenolide Natural products C1C2=C3C=CC4C5(C)CCC(O)C(C)(CO)C5CCC4(C)C3(C)CCC2(C)C2CC1(C)C(=O)O2 RIARKSMMKCXBML-UHFFFAOYSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 208000004608 Ureteral Obstruction Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- OGJKMZVUJJYWKO-ZDUSSCGKSA-N ac1lh1t2 Chemical compound C([C@@H]1NCCC=2C=C(C(=C3C=21)OC)OC)C13C=CC(=O)C=C1 OGJKMZVUJJYWKO-ZDUSSCGKSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- QQUHMASGPODSIW-ICECTASOSA-N albiflorin Chemical compound O([C@@]12C[C@H]3[C@H](O)C[C@@]1(OC(=O)[C@]32COC(=O)C=1C=CC=CC=1)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QQUHMASGPODSIW-ICECTASOSA-N 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- QMAYBMKBYCGXDH-UHFFFAOYSA-N alpha-amorphene Natural products C1CC(C)=CC2C(C(C)C)CC=C(C)C21 QMAYBMKBYCGXDH-UHFFFAOYSA-N 0.000 description 1
- FSLPMRQHCOLESF-SFMCKYFRSA-N alpha-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C FSLPMRQHCOLESF-SFMCKYFRSA-N 0.000 description 1
- SJMCNAVDHDBMLL-UHFFFAOYSA-N alpha-amyrin Natural products CC1CCC2(C)CCC3(C)C(=CCC4C5(C)CCC(O)CC5CCC34C)C2C1C SJMCNAVDHDBMLL-UHFFFAOYSA-N 0.000 description 1
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 description 1
- PSVBPLKYDMHILE-UHFFFAOYSA-N alpha-humulene Natural products CC1=C/CC(C)(C)C=CCC=CCC1 PSVBPLKYDMHILE-UHFFFAOYSA-N 0.000 description 1
- OZQAPQSEYFAMCY-UHFFFAOYSA-N alpha-selinene Natural products C1CC=C(C)C2CC(C(=C)C)CCC21C OZQAPQSEYFAMCY-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000003509 anti-fertility effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000003402 anti-promotion Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 108700000707 bcl-2-Associated X Proteins 0.000 description 1
- 102000055102 bcl-2-Associated X Human genes 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- 229930014717 bisabolane Natural products 0.000 description 1
- NOWQRWPUNHMSAF-UHFFFAOYSA-N bisabolane Chemical compound CC(C)CCCC(C)C1CCC(C)CC1 NOWQRWPUNHMSAF-UHFFFAOYSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- MUYJSOCNDLUHPJ-UHFFFAOYSA-N bishydrocurcumin Natural products C1=C(O)C(OC)=CC(CCC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 MUYJSOCNDLUHPJ-UHFFFAOYSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229930185781 brachystemidine Natural products 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 229930002314 cadinol Natural products 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229930006741 carane Natural products 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- JIUWTCXNUNHEGP-GJHPUSIBSA-N cardenolide Chemical compound C1([C@H]2CC[C@@H]3[C@H]4[C@@H]([C@]5(CCCCC5CC4)C)CC[C@@]32C)=CC(=O)OC1 JIUWTCXNUNHEGP-GJHPUSIBSA-N 0.000 description 1
- 230000003684 cardiac depression Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- SVURIXNDRWRAFU-OGMFBOKVSA-N cedrol Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@@H]1[C@@](O)(C)CC2 SVURIXNDRWRAFU-OGMFBOKVSA-N 0.000 description 1
- PCROEXHGMUJCDB-UHFFFAOYSA-N cedrol Natural products CC1CCC2C(C)(C)C3CC(C)(O)CC12C3 PCROEXHGMUJCDB-UHFFFAOYSA-N 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000001215 curcuma longa l. root Substances 0.000 description 1
- ISFMXVMWEWLJGJ-NZBPQXDJSA-N curcumenol Chemical compound CC1=C[C@](O2)(O)C(=C(C)C)C[C@@]22[C@@H](C)CC[C@H]21 ISFMXVMWEWLJGJ-NZBPQXDJSA-N 0.000 description 1
- KDPFMRXIVDLQKX-UHFFFAOYSA-N curdione Natural products CC(C)C1CC(=O)C(C)CCC=C(C)CC1=O KDPFMRXIVDLQKX-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- YOCDGWMCBBMMGJ-UHFFFAOYSA-N delta-cadinene Natural products C1C=C(C)CC2C(C(C)C)CCC(=C)C21 YOCDGWMCBBMMGJ-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- MUYJSOCNDLUHPJ-XVNBXDOJSA-N dihydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 MUYJSOCNDLUHPJ-XVNBXDOJSA-N 0.000 description 1
- BWHPKBOLJFNCPW-UHFFFAOYSA-N dihydrocurcumin Natural products C1=C(O)C(OC)=CC(CCC(=O)C=C(O)C=CC=2C=C(OC)C(O)=CC=2)=C1 BWHPKBOLJFNCPW-UHFFFAOYSA-N 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- FSKPDOZBWMKQBY-UHFFFAOYSA-N discretine Natural products C1C2=CC(OC)=C(OC)C=C2CN2C1C(C=C(C(=C1)O)OC)=C1CC2 FSKPDOZBWMKQBY-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- GQTWBRFNZHWIEF-WDYWJOCVSA-N disinomenine Natural products COC1=C[C@@H]2[C@@H]3Cc4c(c(OC)cc(O)c4[C@]2(CCN3C)CC1=O)c5c6C[C@H]7[C@H]8C=C(OC)C(=O)C[C@@]8(CCN7C)c6c(O)cc5OC GQTWBRFNZHWIEF-WDYWJOCVSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 125000001513 elemane group Chemical group 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 210000003013 erythroid precursor cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- KLFIUQCKSSAFFU-ANNBSXMPSA-N galloylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=C(O)C(O)=C(O)C=2)O1)O)C)OC(=O)C1=CC=CC=C1 KLFIUQCKSSAFFU-ANNBSXMPSA-N 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 229930001431 germacrane Natural products 0.000 description 1
- IBMAYSYTZAVZPY-QDMKHBRRSA-N germacrane Chemical compound CC(C)[C@H]1CC[C@@H](C)CCC[C@@H](C)CC1 IBMAYSYTZAVZPY-QDMKHBRRSA-N 0.000 description 1
- 229930184727 ginkgolide Natural products 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- UZIOUZHBUYLDHW-XUBRWZAZSA-N ginsenoside Rf Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZIOUZHBUYLDHW-XUBRWZAZSA-N 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 125000002168 glycyrrhetinic acid group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- ZRBFCAALKKNCJG-SJYBZOGZSA-N gypenoside XVII Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZRBFCAALKKNCJG-SJYBZOGZSA-N 0.000 description 1
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 210000001357 hemopoietic progenitor cell Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229930184660 homalomenol Natural products 0.000 description 1
- DHUDRGOPTAAHRB-UHFFFAOYSA-N homalomenol C Natural products CC(C)C1CCC2(C)C1C3OC2(O)CCC3(C)O DHUDRGOPTAAHRB-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- RJGBSYZFOCAGQY-UHFFFAOYSA-N hydroxymethylfurfural Natural products COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 1
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 1
- 235000008718 isoliquiritigenin Nutrition 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- OWDQPILTDJLGCN-UHFFFAOYSA-N isosinomenine Natural products C1C2=CC=C(OC)C(O)=C2C23C=C(OC)C(=O)CC3C1N(C)CC2 OWDQPILTDJLGCN-UHFFFAOYSA-N 0.000 description 1
- SVURIXNDRWRAFU-UHFFFAOYSA-N juniperanol Natural products C1C23C(C)CCC3C(C)(C)C1C(O)(C)CC2 SVURIXNDRWRAFU-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 150000002561 ketenes Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- GGWMNTNDTRKETA-UHFFFAOYSA-N licoricone Chemical compound COC1=C(CC=C(C)C)C(OC)=CC(O)=C1C1=COC2=CC(O)=CC=C2C1=O GGWMNTNDTRKETA-UHFFFAOYSA-N 0.000 description 1
- GYCKPTRFNFHGGO-UHFFFAOYSA-N licorinone Natural products COc1cc(O)c(C2=COc3cc(O)cc(O)c3C2=O)c(OC)c1CC=C(C)C GYCKPTRFNFHGGO-UHFFFAOYSA-N 0.000 description 1
- GDAAEAXMNLVRCZ-SFHVURJKSA-N licorisoflavan A Chemical compound C1([C@@H]2COC=3C=C(C(=C(OC)C=3C2)CC=C(C)C)OC)=CC=C(O)C(CC=C(C)C)=C1O GDAAEAXMNLVRCZ-SFHVURJKSA-N 0.000 description 1
- GBRZTUJCDFSIHM-UHFFFAOYSA-N licorisoflavan B Natural products C1C=2C(OC)=C(CC=C(C)C)C(O)=CC=2OCC1C1=CC=C(O)C(CC=C(C)C)=C1O GBRZTUJCDFSIHM-UHFFFAOYSA-N 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 1
- USOSNFWVEWONDB-UHFFFAOYSA-N liriodendrin Natural products COc1cc(cc(OC)c1OC2OC(CO)C(O)C(O)C2O)C3OC(C)(C)C4C(OC(C)(C)C34)c5cc(OC)c(OC6OC(CO)C(O)C(O)C6O)c(OC)c5 USOSNFWVEWONDB-UHFFFAOYSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000005405 multipole Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000008065 myocardial cell damage Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- NAJPAGUETSZHOG-UHFFFAOYSA-N n-butyl-beta-D-fructopyranoside Natural products CCCCOC1(CO)OCC(O)C(O)C1O NAJPAGUETSZHOG-UHFFFAOYSA-N 0.000 description 1
- BJJRDCBDIOEIKD-IUUKEHGRSA-N n-demethylsinomenine Chemical compound C([C@H]1NCC2)C3=CC=C(OC)C(O)=C3[C@]32[C@H]1C=C(OC)C(=O)C3 BJJRDCBDIOEIKD-IUUKEHGRSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- MGJLSBDCWOSMHL-MIUGBVLSSA-N ononin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=C2C1=O MGJLSBDCWOSMHL-MIUGBVLSSA-N 0.000 description 1
- MGJLSBDCWOSMHL-UHFFFAOYSA-N ononoside Natural products C1=CC(OC)=CC=C1C1=COC2=CC(OC3C(C(O)C(O)C(CO)O3)O)=CC=C2C1=O MGJLSBDCWOSMHL-UHFFFAOYSA-N 0.000 description 1
- SOZSXJHFVBBAOY-TUVASFSCSA-N oplodiol Chemical compound O[C@@H]1CC[C@](C)(O)[C@@H]2CC(C(C)C)=CC[C@]21C SOZSXJHFVBBAOY-TUVASFSCSA-N 0.000 description 1
- WLPKWEUOGCCCIB-UHFFFAOYSA-N oplopanone Natural products CC(C)C1CCC(C)(O)C2CCC(C(=O)C)C12C WLPKWEUOGCCCIB-UHFFFAOYSA-N 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000009835 oxypaeoniflora Substances 0.000 description 1
- FCHVXNVDFYXLIL-QYDSDWLYSA-N oxypaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=C(O)C=C1 FCHVXNVDFYXLIL-QYDSDWLYSA-N 0.000 description 1
- RLXWQODPAWIVOI-UHFFFAOYSA-N oxypaeoniflorin Natural products OCC1OC(OC23CC4C5(O)CC2OC(O5)C34COC(=O)c6ccc(O)cc6)C(O)C(O)C1O RLXWQODPAWIVOI-UHFFFAOYSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- OGJKMZVUJJYWKO-UHFFFAOYSA-N proaporphine Natural products C1=2C3=C(OC)C(OC)=CC=2CCNC1CC13C=CC(=O)C=C1 OGJKMZVUJJYWKO-UHFFFAOYSA-N 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 229930002341 quinoline alkaloid Natural products 0.000 description 1
- 108700038606 rat Smooth muscle Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- PPRSVUXPYPBULA-UHFFFAOYSA-N saponin A Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O PPRSVUXPYPBULA-UHFFFAOYSA-N 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- VPQBJIRQUUEAFC-UHFFFAOYSA-N selinene Natural products C1CC=C(C)C2CC(C(C)C)CCC21C VPQBJIRQUUEAFC-UHFFFAOYSA-N 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- USDOQCCMRDNVAH-UHFFFAOYSA-N sigma-cadinene Natural products C1C=C(C)CC2C(C(C)C)CC=C(C)C21 USDOQCCMRDNVAH-UHFFFAOYSA-N 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- LQGMCNYUEUTNAW-UHFFFAOYSA-N sinomendine Chemical compound C1=CC2=CC(OC)=CC(C=3C(=C(OC)C(OC)=CC=3)C3(O)C)=C2C3=N1 LQGMCNYUEUTNAW-UHFFFAOYSA-N 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- MOCOXAJEZKHXSF-IHMBCTQLSA-M sodium;(2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound [Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MOCOXAJEZKHXSF-IHMBCTQLSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LHYHMMRYTDARSZ-YJNKXOJESA-N t-cadinol Natural products C1CC(C)=C[C@@H]2[C@H](C(C)C)CC[C@](C)(O)[C@@H]21 LHYHMMRYTDARSZ-YJNKXOJESA-N 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical group N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical compound OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- XOCANRBEOZQNAQ-UHFFFAOYSA-N α-turmerone Chemical compound CC(C)=CC(=O)CC(C)C1CC=C(C)C=C1 XOCANRBEOZQNAQ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses traditional Chinese medicine capsules for treating rheumatoid arthritis and a preparation method thereof. The traditional Chinese medicine capsules are prepared from traditional Chinese medicines including hot rhizoma cibotii, zaocys dhumnades, obscured homalomena rhizome, periploca forrestii schltr, caulis sinomenii, panax pseudoginseng, rhizoma curcumae longae, radix paeoniae alba, liquorice and microcrystalline cellulose. The traditional Chinese medicine capsules disclosed by the invention are exact in curative effect, safe and reliable, convenient to take, quick in drug release, economical and practical in price and convenient to carry, thereby bringing more medication choices to the patients.
Description
Technical field
The present invention relates to technical field of Chinese medicines, particularly relate to a kind of Chinese medicinal capsule for the treatment of rheumatoid arthritis and preparation method thereof.
Background technology
Rheumatoid arthritis is one of clinical modal rheumatism immunological disease, and its morbidity is filled with disability rate high, and in onset 1 year, disability rate can reach 60% in up to 20%, 10 year, is to cause in the world one of disabled principal disease, and the title of " dead cancer " is arranged.China's RA annual morbidity is about 0.32-0.36%, and the onset peak age is 45-55 about year, and its prevalence increases with the increase at age.According to estimates, there is the about 400-500 ten thousand of adult RA patient in China, and its person in middle and old age RA accounts for 1,200,000, and at China l3 more than hundred million in population, the RA patient Ke Da 400,000 newly increased every year.Foreign data shows, because of medical expense and joint, disables and loses the financial burden that work causes to society, has influence on the population of global 0.5%-1%.Due to its pathogenetic uncertainty, at present treatment mainly take alleviate arthralgia, the control disease progression is main purpose, common drug is as nonsteroidal antiinflammatory drug, glucocorticoid, immunosuppressant etc., because of the toxic and side effects of these medicines large, cause a lot of patients to be difficult to adhere to medication, although the biological preparation that recent years abroad is introduced has shown good therapeutic effect as tumor necrosis factor antagonists etc., but because Time To Market is short, lack long-term adverse reaction monitoring, add expensive, most of patient is difficult to bear, and clinical practice is restricted.And it is also rare to use Chinese medicine preparation to treat the active drug of this disease, how to make the vast Chinese medicine of motherland can apply to the treatment field of this disease, become traditional Chinese medical science worker's a urgent task.
Summary of the invention
Technical problem to be solved by this invention is the defect that overcomes prior art, and a kind of determined curative effect is provided, safe and reliable, taking convenience, release is rapid, easy to carry, Chinese medicinal capsule of the treatment rheumatoid arthritis of price economy material benefit and preparation method thereof, select for the patient provides more medication.
In order to solve the problems of the technologies described above, the present invention adopts following technical scheme:
According to listed as parts by weight, the Chinese medicinal capsule that the present invention treats rheumatoid arthritis is to scald Rhizoma Cibotii 200~400g Zaocys 100~300g Rhizoma Homalomenae 200~400g Heiguteng exract 150~350g Caulis Sinomenii 500~700g Radix Notoginseng 40~100g Rhizoma Curcumae Longae 300~500g Radix Paeoniae Alba 500~700 g Radix Glycyrrhizae 80~160g microcrystalline Cellulose 60~110g by raw material of Chinese medicine to be prepared from.
Preferably, above-mentioned Chinese medicinal capsule is by boiling hot Rhizoma Cibotii 312.5g Zaocys 208.3g Rhizoma Homalomenae 312.5g
Heiguteng exract 187.5g Caulis Sinomenii 625.0g Radix Notoginseng 62.5g Rhizoma Curcumae Longae 416.7g Radix Paeoniae Alba 625.0g Radix Glycyrrhizae 125.0g microcrystalline Cellulose 85g is prepared from.
The present invention also provides the preferred preparation method of aforementioned Chinese medicinal capsule: it is standby that Radix Notoginseng breaks into fine powder, the water soaking that all the other 8 flavor medicines add 9.3 times of amounts for the first time decocted 0.5 hour after 1 hour, the decocting that second and third time respectively adds 8 times of amounts boils, each 0.5 hour, merge decocting liquid 3 times, filter, it is 1.35~1.40(60 ℃ that the filtrate normal pressure is concentrated into relative density) thick extractum, be placed in 80 ℃ of constant pressure and dries, broken mistake 65 mesh sieves of dried cream powder are mixed homogeneously with Radix Notoginseng powder, microcrystalline Cellulose, the 0# hard capsule and get final product of packing into.
Trade name of the present invention: Golden Crow Jiangu capsule for strengthening bone
Monarch drug of the present invention scalds Rhizoma Cibotii invigorating the liver and kidney, strong spinal column, wind-damp dispelling, the Zaocys wind-damp dispelling, restores menstrual flow and invigorates blood circulation; Ministerial drug Rhizoma Homalomenae, Heiguteng exract, Caulis Sinomenii wind-expelling pain-stopping, strengthening the tendons and bones; Adjuvant drug Radix Notoginseng, Rhizoma Curcumae Longae promoting blood circulation and stopping pain; Make the medicine Radix Paeoniae Alba, the Radix Glycyrrhizae stomach function regulating that nourishes blood, relieving spasm to stop pain.Full side has the effect of reinforcing the kidney to strengthen the bone, promoting blood circulation, dredging meridian and relieving pain, make that muscles and bones is strong, loose through ruton, strongly fragrant heresy, blood stasis, heresy is moved back and is not just being hindered, from the kidney invigorating, strong muscle, strong bone, invigorate blood circulation, nourish blood, dispel the wind, the multi-angle prescriptions such as dredging collateral, analgesic therapy, shape is loose and power is special, coordinates precise and appropriate.The inventor confirms that in clinical research the strong bone side of the Golden Crow has good efficacy to the treatment of RA, especially alleviate RA patient clinical symptom, reduce antirheumatic and shown clinical efficacy preferably as the toxic and side effects aspect of methotrexate etc., it is furtherd investigate, inquire into its treatment mechanism, improve treatment, the quality of making the life better of RA, there is wide potential applicability in clinical practice.
Usage and consumption: oral each 4, every day 3 times.
experiment one: preparation process research
One, the selection foundation of process route
(1) prescription drug physicochemical property and pharmacological research
scald Rhizoma Cibotii(Dicksoniaceae plant Rhizoma Cibotii
cibotium barometz(L.) dry rhizome of J. Sm., remove silt, remove hard root, petiole and golden yellow fine hair, cut sheet, drying is scalded method according to appendix II D of Chinese Pharmacopoeia version in 2010 again, with stir-baking in sand, to heaving, removes remaining fine hair after cooling) according to documents and materials, boiling hot Rhizoma Cibotii chemical composition is summed up and mainly contains following a few class: volatile oil: main component is higher fatty acids, and what content was the highest is Palmic acid, linoleic acid; The pterosin class: gold hair pterosin, onychin-2 '-O-β-D-pyranglucoside, onychin-15 '-O-β-D-pyranglucoside; Water-soluble phenolic compounds: protocatechuic acid, caffeic acid; Aromatic compound: protocatechuic acid, protocatechualdehyde, the old element of the luxuriant Di Bo of (3R)-go-O-methyl, Rhizoma Cibotii glycosides; Flavonoid: kaempferide; Saponins: Rhizoma Cibotii saponin; Glucide compounds: n-Butyl-β-D-fructopyranoside, glucose, sucrose, maltose, 5 hydroxymethyl furfural, 3-hydroxyl-gamma-pyrone; Also contain aminoacid (aspartic acid, glutamic acid and proline content are higher); (content with K is the highest for inorganic elements, next is Mn), and the compounds such as cupreol, cupreol-3-O-(6 '-positive palmityl oxygen base)-3-β-D-Glucose glycosides, cupreol-3-O-(6 '-positive n acyloxy)-β-D-Glucose glycosides, cupreol-β-D-Glucose glycosides (daucosterol), stearic acid, tannin, acetanilide phosphatidylcholine (PC).
Scald Rhizoma Cibotii bitter in the mouth, sweet, warm in nature.Return liver, kidney channel.There is wind-damp dispelling, invigorating the liver and kidney, strong waist knee joint.For rheumatic arthralgia, soreness of the waist and knees, weakness of the lower extremities.Miao ethnic group's medicine is thought " nest have to add slip " (Rhizoma Cibotii) bitter in the mouth, sweet, and property is cold, enters hot warp.The modern pharmacological research data shows, Rhizoma Cibotii may have the bone of increasing activation frequency and stimulate osteoplastic effect, prevents and treats osteoporosis.Water soluble ingredient in the stir-baking in sand Rhizoma Cibotii, significantly anticoagulant.Rhizoma Cibotii and processed product thereof and Rhizoma Cibotii hair have analgesic activity and the effect of invigorating blood circulation in various degree.Rhizoma Cibotii can improve adjuvant arthritis rats and insufficiency of kidney-YANG adjuvant arthritis rats hemorheological property, by blood circulation promoting and blood stasis dispelling, plays certain therapeutical effect, and stir-baking in sand acts on and strengthening after concocting.The fragrant acids composition protocatechuic acid of water solublity and caffeic acid, have antiinflammatory, antiheumatic pharmacologically active.Onychin has hepatoprotective effect, also can remove peroxide and free radical.In vitro tests shows, Rhizoma Cibotii has certain bacteriostasis, and infected by influenza, Diplococcus pneumoniae have inhibitory action.
zaocys(Colubridae animal Zaocys
zaocys dhumnades(Cantor) dry body) according to documents and materials, the Zaocys chemical composition is mainly amino acids: mainly containing aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, cystine, cysteine, valine, methionine, isoleucine, tyrosine, phenylalanine, lysine, histidine, methionine, leucine, arginine, γ-aminobutyric acid etc.; And inorganic elements, protein, fat, ester of Harden Young esterase, Serpentis flesh aldehyde lyase and collagen protein etc.Separate and obtain from the methanolic extract of Zaocys, brachystemidines A, butyl phthalate isobutyl ester, dihydro ferulic acid, cupreol, thymus pyrimidine, 4-hydroxy benzaldehyde.
The Zaocys sweet in the mouth, property is flat.Return Liver Channel.Have and dispel the wind, dredging collateral, the effect of relieving convulsion.For rheumatoid stubborn weakness, numbness Spasm, oblique of outlet eye , hemiplegia, convulsions convulsions, tetanus, leprosy, scabies.Miao ethnic group's medicine is thought " can lattice emit " (Zaocys) salty in the mouth, the property slight fever.Enter slow warp, half of warp.Modern pharmacological research shows, Zaocys has calmness, anti-frightened, analgesia, antiinflammatory action.Zaocys II Collagen Type VI has identical immunoregulation effect with cattle II Collagen Type VI, and both can lower rats with arthritis peripheral blood TNF-a level, anti-II Collagen Type VI antibody titer and CD
4+/CD
8+ ratio, the effect that improves the IL-10 level, infer that Zaocys II Collagen Type VI may be the active pharmaceutical component of Zaocys treatment RA.Zaocys hydrolyzed solution treatment rheumatoid arthritis total effective rate is 64.2%, and obvious effective rate is 16.7%, apparently higher than 38.3%, 6.7% of placebo group.Its suitableeest pattern of syndrome is intermingled phlegm and blood stasis type.
rhizoma Homalomenae(aroid Rhizoma Homalomenae
homalomena occulta(Lour.) dry rhizome of Schoot, two seasons of spring and autumn excavate, and clean, and remove crust, dry) according to documents and materials, from Rhizoma Homalomenae chloroform and ethyl acetate extract, separate and identify 7 compounds, cupreol, β-daucosterol; Other 5 is sesquiterpenoids, is respectively sesquiterpene (1) oplodiol, (2) oplopanone, (3) homalomenol C, (4) bullatantriol and (5) 1 β, 4 β, 7 α-trihy-droxyeudesmane; Be divided into from and identified 6 compounds from petroleum ether and n-butanol portion, three compounds comprising petroleum ether part, be respectively: Alpha-hydroxy 25 carbonic acid, three compounds of Palmic acid and 15 carbonic acid and n-butanol portion, they are respectively: glucose, D-galactitol and red bright alcohol; Volatile ingredient is: γ-terpinene, linalool, terpineol-4, acetic acid Lignum cinnamomi camphorae alcohol ester, γ-Cananga odorata oil alkene, β-caryophyllene, α-humulene, α-selinene, (-)-α-Cananga odorata oil alkene, α-purple favour Chinese scholartree alkene, δ-cadinene, α-cedrol, tertiary cadinol, tertiary fragrant cananga oleyl alcohol, (Z)-6,10-dimethyl-5,9-decadinene-2-ketone, 2-amino-3-hydroxy formic acid etc.
Rhizoma Homalomenae bitter in the mouth, suffering, warm in nature.Return liver, kidney channel.There is wind-damp dispelling, the effect of strengthening bone and muscle.For anemofrigid-damp arthralgia, chills and pain of the waist and kness, the contracture numbness, the muscles and bones flaccidity is soft.The modern pharmacological research data shows that Rhizoma Homalomenae has following pharmacological action: (1) is antibiotic, antiviral: the experiment of filter paper flat band method shows that Essential Oil from Homalomena Occulta Schott by GC-MS can suppress the growth of Brucella fully; The Rhizoma Homalomenae water extract is external can also suppress I type herpes simplex virus (HSV-1); (2) antiinflammatory, analgesia: the Rhizoma Homalomenae methanolic extract can obviously suppress the rat toes swelling that carrageenin causes, also can effectively suppress the mouse writhing reaction that acetic acid causes; (3) antihistamine: the guinea-pig isolated trachea Faxian shows the guinea pig tracheal smooth muscle contraction that homalomenol extract energy antagonism histamine causes; (4) anticoagulation: the Rhizoma Homalomenae water extract has stronger blood coagulation resisting function; (5) other: Rhizoma Homalomenae also has the activity that suppresses calcium channel blocker receptor and angiotensin-ii receptor.
heiguteng exract(asclepiadaceae plant Caulis et Radix Periplocae Forrestii
periploca forrestiischltr. dry root) according to documents and materials research, the contained compound of Heiguteng exract mainly contains following a few class: rhizome is containing the cardenolide Ginkgolide Component Yunnan P. sepium Bunge former times A of unit and Yunnan periplocoside, daucosterol, ursolic acid, 8-hydroxyl periplogenin, periplogenin, periplocoside, periploca sepium glycosides; Diterpene quinone: Tanshinone I I
a; Glycosides compound, be respectively: emodin-8-O-β-D-Glucose glycosides, physcione-8-O-β-D-Glucose glycosides, Kaempferol-O-β-D-galactoside, Kaempferol-O-α-L-arabopyranose glycosides, Quercetin-3-O-β-D-pyranglucoside, Quercetin-3-O-α-L-arabopyranose glycosides.Extract Guizhou Province by steam distillation and produce Heiguteng exract Herb volatile oil, utilize the retrieval in GC-MS multiple techniques combined standard spectrum storehouse, from 44 compounds that obtain, identified 27 kinds of compositions, detect composition and account for 93. 2% of volatile oil component.Wherein palmitic acid content is the highest, accounts for 45. 6% of volatile oil total amount.Heiguteng exract volatile oil component and content thereof are produced in clear and definite Guizhou Province, for improving its comprehensive development and utilization, provide experimental basis.
Heiguteng exract bitter in the mouth, suffering, cool in nature; Slightly poisonous.Miao ethnic group's medicine is thought " the big plug of the frog " (Heiguteng exract) acrid in the mouth, hardship, hot in nature; Slightly poisonous.Enter cold warp.There is relaxing muscles and tendons to promote blood circulation, the effect of expelling wind and removing dampness.Cure mainly rheumatic arthralgia, amenorrhea, acute mastitis, injury from falling down, fracture, stomatitis, stomachache, dyspepsia, malaria.The modern pharmacology research data shows: α
2amyrin and β-Amyrin acetas has obvious antagonism to arthritis; α-Amyrin acetas and β-Amyrin acetas can suppress granuloma induced by implantation of cotton pellets, and its effect is similar to hydrocortisone; β-Amyrin acetas can make liver homogenate ATP phosphohydrolase obviously raise, this and Heiguteng exract
antiinflammatory actionmatch.Ursolic acid has and suppresses active gram positive bacteria, negative bacterium, yeast in vitro, can obviously reduce the normal body temperature of rat, and stable effect (antibacterial action) is arranged.Emodin has the effect of stronger anti-tumor activity and cell death inducing, and emodin is by activating p
53, p
21expression, can effectively suppress hepatoma carcinoma cell HepG in vitro
2propagation and induce its apoptosis, its half-inhibition concentration 130 μ mol/L.Emodin can also be induced lung cancer cell line H
460, CL
5apoptosis.β-daucosterol is a kind of antitumor drug, has antifungal activity.Therefore the chemical substance basis of Heiguteng exract medical value has been illustrated in the discovery of these compounds to a certain extent.Propose total glycosides in the fresh peel of stem of Heiguteng exract, through the frog heart in place and Cor Leporis, Cor Leporis electrograph and guinea-pig heart test, prove cardiotonic, the similar strophanthoside G of its cardiotonic characteristics, and the Columba livia mean lethal dose (MLD) is 5.9 ± 1.0 mg/Kg.Adopt mouse writhing method and hot plate method, Heiguteng exract has obvious analgesic activity.By the experiment of mice caused by dimethylbenzene xylene auricle swelling degree, each extract part of Heiguteng exract all can make the mice ear degree reduce in various degree; Cause the experiment of mice capillary permeability by acetic acid, Heiguteng exract has the effect that capillary permeability increases that suppresses.HGT-5A 100~500 mgKg
-1the chmice acute ear swelling that gastric infusion brings out Oleum Tiglii has obvious inhibitory action, 100~500 mgKg
-1the DTH reaction that gastric infusion is induced DNCB has obvious inhibitory action, and breeder reaction all has obvious inhibitory action to DTH model mice splenocyte.Heiguteng exract has good anti-RA effect, its mechanism of action may with regulate immune organ function and proinflammatory cytokine IL-1 β, IL-6, the contents level of TNF-α is relevant.
caulis Sinomenii (the menispermaceous plants Sinomenium acutum
sinomenium acutum(Thunb.) Rehd. et Wils. and hair Sinomenium acutum
s. acutum(Thunb.) Rehd. et Wils. var.
cinereumrehd. the dry rattan of et Wils..Time of the year when autumn changes into winter taps, binding or cut long section, dry) according to the rattan of documents and materials Caulis Sinomenii mainly containing the alkaloids composition: sinomenine, sinoacutine, the Sinomenium acutum menispermine, N-demethyl Sinomenium acutum menispermine, N-oxidation sinomenine, N-demethyl sinomenine, sharp sinoacutine falls, disinomenine, the tetrahydrochysene epiberberine, soil rattan alkali, magnoflorine, isosinomenine, michelalbine, stepharine, 8, 14-dihydro Sa Lutaliding alkali, sinomendine, stepharanine alkali, bianfugenine alkali, N-demethyl-N-formoxyl dehydronuciferine, liriodendrin, Caulis menispermi is appointed alkali, laurifoline, the dehydrogenation discretine, epiberberine, palmatine, acutupyrrocoline.Wherein sinomenine is main active component, and rattan is thicker, and the content of sinomenine is higher.
Caulis Sinomenii bitter in the mouth, suffering, property is flat.Return liver, spleen channel.The modern pharmacological research data shows, Caulis Sinomenii has following pharmacological action: (1) antiinflammatory: sinomenine is external can obviously reduce the mouse peritoneum macrophage synthesis of prostaglandins E that zymosan or Calcium ionophore are induced
2(PGE
2) and leukotriene C
4(LTC
4); To acute arthritis (AIA) model of rat antigen induction, short-term or mid-term the lumbar injection sinomenine can alleviate arthroncus, the erythrocyte sedimentation rate that slows down (ESR); Observe sinomenine to the lymphocyte effect with external mouse boosting cell core human peripheral blood single nucleus cell, find that sinomenine suppresses lymphocytic propagation and has reversibility, and can increase the generation of interleukin 6 (IL-6), suppress interleukin-22 (IL-2) membrane receptor and express; The external energy of sinomenine produces the resisting rheumatoid arthritis effect by downward human peripheral blood single nucleus cell IL-1 β, IL-8 mrna expression; To collagen Ⅱ induced arthritis (CIA) rat, the sinomenine gavage can be blocked periostitic process by the expression that suppresses periosteum cell malignant proliferation and IL-6 mRNA.Further Anti-inflammatory Mechanism research finds that sinomenine may be by lowering the synthetic performance of Monocytes/Macrophages system inflammation medium and cytokine antiinflammatory action, and be that dose dependent ground significantly reduces T cell within a cell factor TNF-γ, the TNF-alpha molecule is expressed, also may with its inhibition nuclear factor NFkBp
65the degraded of core displacement and inhibitive factor IkB-α thereof is relevant with inhibition nuclear factor NF-kB activity.In addition, vitro enzyme reaction experiment system and the experiment of lipopolysaccharide-induced neurocyte proliferation also find, sinomenine is to Cycloxygenase-2(COX-2) due to PGE
2synthetic table reveals stronger inhibitory action; Further investigation shows, sinomenine has certain selective inhibitory to the COX-2 activity, and may mainly by the direct effect to the COX enzymatic activity, realize.(2) immunosuppressant: observe after sinomenine is transplanted the ACI-Lewis mouse heart allograft rejection effect produced, find the time-to-live that transplant in lumbar injection sinomenine energy Yancheng.The sinomenine experiment in vitro shows to reduce the combination of thymidine in active T lymphocyte, the synthetic and cell cycle cycle of IL-2; Its mechanism of action may be to suppress the Th1 cell to produce IL-2, and the suppressor T cell subgroup also may be by suppressing peripheral blood cd4 cell propagation, lowers the expression of TNF-α, IFN-γ (IFN-γ) and produces the immunosuppressive action to allograft; In addition, with experimental autoimmune encephalomyelitis rat tail model, find, the immunosuppressive action of sinomenine is with to suppress cerebral tissue NF-kB activity relevant, and this inhibitory action may with increase cortisol secretion, the inhibition prolactin secretion is relevant.(3) on the impact of cardio-cerebrovascular: 1. blood pressure lowering, the isolated rabbit smooth muscle cell proliferation reaction that sinomenine stimulates Endothelin has inhibitory action, also can suppress DNA synthetic, and the hypotensive activity that this may be obvious and lasting with sinomenine is relevant.2. arrhythmia, the single cell of ventricular myocytes of guinea pig film sodium ion electric current (INa) that the research sinomenine separates enzyme, the impact of L-type calcium current (ICa-L) are found, sinomenine is to INa and the effect of ICa-L tool rate dependent block, and this may be its antiarrhythmic important mechanism; Sinomenine also has the concentration dependent retardation to Ventricular Myocytes inward rectification potassium current (IK-L) and Delayed Rectifier Potassium Current (Ik), and its multipole effectiveness that extends myocardial cell may block relevant with potassium channel.3. Cardiac depression; pour into respectively sinomenine and isomers 8 thereof; 14-dihydro Sa Lutali pyridine alkali (DHS) is given normal Isolated Working Rat Hearts; posting a letter, both have direct repression to heart; the contraction power of heart is reduced, and DHS have obvious protective effect to the diastolic function of cerebral ischemic rats heart.4. anti-angiogenic rebirth, the sinomenine in vitro and in vivo all can suppress the vascularization that basic fibroblast growth factor (bFGF) causes, and also can reduce vascular permeability, suppresses the granulocyte migration, thereby plays the effect of rheumatoid arthritis (RA); 5. blood vessel dilating, the external Ca that suppresses of sinomenine
2+the activity of passage and Protein kinase C (PKC), increase endothelial cell nitric oxide (NO) and prostacyclin (PGI
2) activity, there is the vasodilator effect.(4) suppress morphine: with incremental dose method, form the morphine mouse model, and urge and giving up with naloxone after the injection sinomenine, find that the sinomenine lumbar injection can suppress the morphine-dependent mice Inhibits Withdrawal Syndromes, significantly alleviate the weight loss of addiction Mouse and rat, its mechanism may be relevant with the disorder of adjusting monoamine neurotransmitter; Test and also show that the Caulis Sinomenii water extract also can suppress the withdrawal symptom of morphine by isolated guinea pig ileum; Caulis Sinomenii alcohol extract or sinomenine also all can effectively suppress the withdrawal symptom that morphine model naloxone is urged in vivo and in vitro; In addition, continuously gavage also can obviously suppress the formation of the mice Place Preference that morphine causes, and the established conditioned place preference effect of mice is also had to certain inhibitory action.(5) analgesia: sinomenine gavage or subcutaneous injection all have inhibitory action to the reaction of shouting due to the writhing response due to mice acetic acid, electricity irritation afterbody.(6) anxiety: the sinomenine oral administration can increase access times and the time of staying of overhead cross labyrinth small mouse to open arms, increase the time of staying and the activity of shading model small mouse at camera-lucida, increase the population exposed time of mice in the population exposed experiment, there is obvious angst resistance effect.
radix Notoginseng(panax araliaceae plant
panax notoginseng(Burk.) dry root of F. H. Chen and rhizome.Excavate before the flowers are in blossom autumn, cleans, and separates main root, supporting root and rhizome, drying) according to documents and materials research, the root and rhizome of Radix Notoginseng contains multiple triterpenoid saponins: arasaponin A, B, C, D, E, G, H, I, J, K, L, M, N, U, R
1, R
2, R
3, R
4, R
6, R
7, ginsenoside Rb
1, Rb
2, Rd, Re, Rg
1, Rg
2, Rh
1, Rh
4, U, 20-O-glucose ginsenoside Rf, Da Ma-20 (22)-alkene-3 β, 12 β, 25-triol-6-O-β-D-pyranglucoside, gypenoside XVII etc.; CYCLIC DIPEPTIDES composition: ring (leucine-threonine), ring (leucine-serine), ring (Ile-Val) etc.; Flavones ingredient: Quercetin etc.; The polysaccharide composition; Sanchinan-A.In addition, also containing the composition such as Radix Notoginseng acid β-sophoroside, dencichine and various trace element etc.
Radix Notoginseng sweet in the mouth, micro-hardship, warm in nature.Return liver, stomach warp.There is the dissipating blood stasis hemostasis, subduing swelling and relieving pain.For spitting of blood, to spit blood, epistaxis, have blood in stool, metrorrhagia, traumatic hemorrhage, breast ventral spine pain, tumbling and swelling.The modern pharmacological research data shows, Radix Notoginseng has following pharmacological action: (1) hemostasis, antithrombotic, promotion hemopoietic: dencichine Rockwell solution lumbar injection can shorten the bleeding time of mice docking.Cooked Radix Notoginseng powder ethanol extract is oral, and mice is had gentle promotion blood coagulation and promotes Fibrinolytic effect.Panax Notoginseng saponin R
1the microcirculation of auricular microcirculation obstacle mice due to normal mouse and norepinephrine be can significantly promote or improve with ginsenoside Rd's subcutaneous injection, blood plasma recalcification time and clotting time extended.The external propagation that can promote people's bone marrow granulocyte (CFU-GM), red system (CFU-E) hemopoietic progenitor cell of Radix Notoginseng total arasaponins, induce the increase of the transcription factor NF-E2 of hematopoietic cell AP-1 family, c-jun, c-fos, with specific DNA, promote son to increase in conjunction with activity, regulate and control the gene expression relevant to the human hematopoietic cell proliferation and differentiation; (2) on the impact of cardiovascular system: arasaponin is external to the open endochylema Ca caused with the calcium channel opening associated with beta receptor of voltage-dependent Ca channel in cardiac myocytes
2+rising has inhibitory action; Radix Notoginseng total arasaponins is external suppresses the propagation of people's fetal blood pipe that hyclone, Hyperlipidemic Serum bring out, rabbit aorta, rat smooth muscle cells (VSMC), suppressing Hyperlipidemic Serum promotes [3H] thymidine to infiltrate the process of cell, reduce Hyperlipidemic Serum and suppress NO release, the retardance cell is in G
0/ G
1phase, reduce the NF-kB activity, thus the performance study of anti-atherogenic effect.The external apoptosis of cardiac muscle that AngiotensionⅡ (AngII) is induced of Radix Notoginseng total arasaponins has remarkable inhibitory action; Gavage can be improved the Acute Myocardial Ischemia Rats cardiac function, and the intravenous injection pretreatment can suppress tumor necrosis factor α (TNF-α) and discharge, and increases the bcl-2 protein expression, reduces the Bax protein expression simultaneously; Compound components of panax notoginseng can strengthen the isolated rat myocardial contraction, decreased heart rate, reduce lipid peroxide (LPO) generation and lactic acid dehydrogenase (LDH), creatine phosphokinase (CPK) release, reduce blood vessel endothelium active factors vaso-excitor material (TXB2) and discharge and the myocardial cell energy expenditure, increase blood vessel endothelium and expand angiogenic substance (PGF
1) discharge, alleviate the rat myocardial cell damage that ischemia-reperfusion causes; (3) protection brain and nervous system: the saponin triol lumbar injection of Radix Notoginseng can raise HSP
70albumen, lower expression of transferrin, reduces brain water content, and the protection blood brain barrier, have protective effect to middle cerebral artery occlusion type rat (MCAO) focal cerebral ischemia, promotes MCAO rat cerebral cell propagation; The expansible cerebrovascular smooth muscle of Radix Notoginseng total arasaponins intravenous injection, reduce cerebral vascular resistance (CVR), lumbar injection can suppress after Focal Ischemia-Reperfusion in Rats the ischemic region cerebral cortex and tail shell core myeloperoxidase (MPO) (MPO) is active, ICAM-1 (ICAM-1) is expressed, neutrophil infiltration, alleviate the inflammatory reaction of cerebral infarction dead band, suppressing matrix metalloproteinase (MMP-9) expresses, alleviate cerebral infarction dead space volume and blood-brain barrier disruption degree, reduce Caudate Nucleus of Rat injectable collagen enzyme induction cerebral hemorrhage hindbrain iron concentration.The thick saponin of Radix Notoginseng, ginsenoside Rd can promote the astrocyte differentiation of culture of neural stem cells neural, the Radix Notoginseng total arasaponins lumbar injection T that can raise
13-L
1prostacyclin (the PGI of joint spinal cord Allen`s injury rats
2), reduce platelet thrombus element A
2(TXA
2), regulate the relation between vasodilation and contraction, increase SCBF, reduce malonaldehyde (MDA) and generate and superoxide dismutase (SOD) activity decreased, alleviate the grey matter district and necrosis occurs, myelin separates and the mitochondrion edema, improve microcirculation disturbance, alleviate Secondary injury, (4) slow down aging: the arasaponin subcutaneous injection can reduce the D-galactose and cause cerebral hippocampal district interleukin-11 β, the increase of interleukin 6 (IL-1 β, IL-6) content that Oxidative Injury causes, and reduces neurocyte Ca
2+overload and apoptosis, improve the aging rats ability of learning and memory and descend, Radix Notoginseng total arasaponins rat oral gavage drug serum, the toxicity of external energy antagonism beta amyloid peptide 25-35 fragment to the NG108-15 neurocyte, promote its growth, gavage can alleviate the D-galactose and merge the minimizing of brain cholinergic neuron quantity and the decline of CAT (ChAT) level that amino-(3-hydroxy-5-isoxazolyl)acetic acid. (IBA) damage causes, but due to intravenous injection antagonism IBA, the dementia rats learning and memory reduces, improve acetylcholine (Ach) in hippocampus, norepinephrine (NE) and dopamine (DA) in cerebral cortex, the neurotransmitter content such as 5-hydroxy tryptamine (5-HT), lumbar injection can improve SOD in the rat body, catalase (CAT), glutathion (GSH) content, (5) protect the liver: the Radix Notoginseng powder gavage can reduce the TNF-α of alcoholic fatty liver in rats, and leptin (Leptin) level alleviates hepatic tissue fat and becomes, Radix Notoginseng total arasaponins is external can significantly suppress cultured rat hepatic stellate cells (HSC) propagation, induces the HSC apoptosis, may be one of mechanism of action of its anti-hepatic fibrosis, (6) anti-hepatic ischemia-reperfusion injury: the Radix Notoginseng total arasaponins specific inhibition is cultivated receptor dependency Ca on rat liver cell membrane
2+passage (ROC), suppress hepatocellular Ca
2+interior stream, blocking-up endogenous InsP3 (IP3) approach, prevent Ca
2+overload, Radix Notoginseng total arasaponins pretreatment Rat Donor Liver, can effectively alleviate the ischemical reperfusion injury that suppresses liver, suppress hepatocellular apoptosis, suppress TNF-α, the expression of caspase-3, suppress oxygen-derived free radicals and generate, raise the expression of controlling gene bcl-2 albumen, and can be by suppressing calcium overload, antioxidant radical damage, promote the multiple mechanism such as metabolism of energy substances to alleviate the damage of rat liver when cryopreservation, (7) anti-kidney region fibrosis: rat renal tubular epithelial cells (NRK52E) transdifferentiation that the external IL-1 of the inhibition α of Radix Notoginseng total arasaponins induces, reduce Extracellular Matrix Secretion, suppress people's renal cells HK-2 propagation and total collagen secretion that Uremic serum is induced, delay the renal tubulointerstitial fibrotic processes, (8) immunoloregulation function: the xylanase extracted in Radix Notoginseng has the activity that suppresses I type HIV (human immunodeficiency virus) (HIV-1) reverse transcriptase, arasaponin gavage energy obvious stimulation mice spleen lymphocytes proliferation, conversion, the effect of promotion Delayed onset allergy, improve mouse antibodies production cell number, serum hemolysin, promote the monocytes/macrophages carbon granule to clean up effect, improve NKT (NK) cytoactive, the arasaponin subcutaneous administration can significantly promote the mouse boosting cell propagation that concanavalin A, Con A (ConA), phytolacca american albumen (PWM), ovalbumin (OVA) are induced, and improves OVA specific IgG, IgG in serum
1, IgG
2bantibody horizontal, lumbar injection can significantly improve burned mouse abdominal cavity Phagocytic Function, reduces NO and produces, and improves the proliferative function of lymphocyte, Radix Notoginseng total glycosides can improve rat polyarthritis due to Freund adjuvant, and this effect may be relevant with the secretion that suppresses serum levels of inflammatory cytokines TNF, IL-1 β.In addition, Radix Notoginseng total glycosides in therapeutic process to rat growthing development unrestraint effect.(9) other: Radix Notoginseng extract also reaches contained ginsenoside Rg
1anti-tumor activity is arranged; Radix Notoginseng total arasaponins can promote the regeneration of adult rat pattern of retinal ganglion cells; Saponin contained in leaf is fed, and can significantly reduce serum cholesterol, the triacylglycerol content of hyperlipidemia rabbit, improves the ratio of high density lipoprotein and cholesterol.In addition, arasaponin also has the effects such as blood sugar lowering, adjusting body substance metabolism.
rhizoma Curcumae Longae(this product is zingiberaceous plant
curcuma longal. dry rhizome.Excavate when stem and leaf is withered winter, clean, boil or steam to the saturating heart, dry, go out fibrous root) according to documents and materials research, the rhizome chemical composition of Rhizoma Curcumae Longae mainly contains: the curcumin material, its mother nucleus structure is diphenyl hydro carbons in heptan, arranged dividing of phenol and non-phenol, also comprise demethoxycurcumin and de-1,7-bis(3,4-dimethoxyphenyl)-1,6-heptadiene-3,5-dione.Diphenylheptane constituents: curcumin, demethoxycurcumin, bisdemethoxycurcumin, letestuianin C, dihydro curcumin, tetrahydrocurcumin; Terpenoid: the main component in Rhizoma Curcumae Longae volatile oil is sesquiterpene and monoterpenes compound, and its structure type mainly contains: germacrane, guainane type, carane type, eudesmane-type, Bisabolane, elemane type, xanthane type etc.Sesquiterpenoids composition: the new ketone of Rhizoma Curcumae Longae, Rhizoma Curcumae Longae keto-alcohol A, B, Germacrone-13-aldehyde, Rhizoma Curcumae dicyclo ketenes, α-turmerone, Bisabolol curcumol, Bisabolol turmerone, curcumenol, procurcumenol, different procurcumenol, table procurcumenol, deoxidation curdione, (+)-germacrone-4,5-epoxide, Rhizoma Curcumae azulene ketone glycol; Alkaloids: isolated quinoline alkaloid 2-(2'-methyl-1'-propenyl)-4,6-dimethyl-7-hydroxyquinoline; Polysaccharide composition: Rhizoma Curcumae Longae Polysaccharide A, B, C, D and trace element.
Rhizoma Curcumae Longae acrid in the mouth, hardship, warm in nature.Return spleen, Liver Channel.There is the removing blood stasis circulation of qi promoting, inducing menstruation to relieve menalgia.For the twinge of the breast side of body, obstruction of qi in the chest and cardialgia, dysmenorrhea amenorrhea, lump in the abdomen, rheumatism shoulder arm pain, tumbling and swelling.Miao ethnic group's medicine think " nest Kazakhstan " (Rhizoma Curcumae Longae) flavor numb, peppery, micro-hardship, hot in nature.Enter cold warp.The modern pharmacology research data shows: Rhizoma Curcumae Longae has following pharmacological action: (1) antiinflammatory, analgesia: the various extract gavages of Rhizoma Curcumae Longae volatile oil and Rhizoma Curcumae Longae can reduce acetic acid induced mice writhing response number of times, and rat toes swelling due to Ovum Gallus domesticus album is had to obvious inhibitory action; In two kinds of rat pancreatic adenitis models that Magainin and ethanol cause in conjunction with the low dosage cholecystokinin, curcumin can obviously improve the indexs such as serum amylase, trypsin and neutrophil cell infiltration; In the curcumin body and external all can be by Janus kinases-STAT(JAK-STAT in blocking-up T lymphocyte) interleukin 12 (IL-12) signal conduction on path, suppress the inflammatory reaction of experimental allergic encephalomyelitis mice; Curcumin is oral to the chronic colitis mice, can increase the activity of myeloperoxidase (MPO) (MPO) and tumor necrosis factor α (TNF-α); (2) anticoagulant: the external Platelet Aggregation in Rabbits that can suppress collagen protein and arachidonic acid-induction in the cyclohexane extraction position of Rhizoma Curcumae Longae rhizome methanolic extract, aryl turmerone is main active; (3) antitumor: curcumin can suppress the growth of human liver cancer cell; Can also, by regulating cellular immune function, prevent the formation of mice intestinal mucosa adenocarcinoma; (4) antibiotic: experiment in vitro shows, Rhizoma Curcumae Longae volatile oil has inhibitory action in various degree to funguses such as the antibacterials such as staphylococcus aureus, bacillus subtilis, diphtheria corynebacterium, escherichia coli, bacillus cereus, Salmonella typhimurium and ANs; The methanolic extract of Rhizoma Curcumae Longae has strong inhibitory action to bacillus aerogenes capsulatus, escherichia coli; The ethyl acetate of Rhizoma Curcumae Longae rhizome, methanol and water extract all can suppress methicillin-resistant Staphylococcus aureus, and ethyl acetate extract can also suppress methicillin-resistant Staphylococcus aureus invasion human mucosa fibroblast effectively.Curcumin is one of bacteriostatic active ingredients; (5) the external antioxidation that can improve rat liver cell membrane of Turmeric Root, eliminate APAP to hepatocellular prooxidant effect; Oral administration can reduce CCl
4the Rat Hepatocyte Injury caused, oxidative stress and the serum transaminase that can also reduce hepatic injury mice due to lumbar injection chlorination pot cadmium raise.The turmeric ethanol extraction can suppress hepatic injury rat blood serum alanine aminotransferase (ALT) due to acetyl aminophenol, aspartate transaminase (AST) and alkali phosphatase (ALP) and raise; Oral administration can suppress Schistosoma mansoni and infect the Mouse Liver dysfunction caused, and can also reduce the level of pyruvate kinase.The curcumin gastric infusion is to CCl
4, the hepatic injury that adds lipopolysaccharide-induced mice of D-galactosamine and bacillus calmette-guerin vaccine all has protective effect; Externally can suppress the Mouse Liver sternzellen-expression of T6I Collagen Type VI and the phosphorylation of extracellular signal-regulated kinase, thereby suppress the hypertrophy of hepatic stellate cell; (6) protect kidney: the curcumin vivo medicine-feeding can raise the expression of antioxidase in mitochondrial matrix, and the injury of kidney that rat ureteral obstruction or ischemia-reperfusion are caused has protective effect; (7) antioxidation: the lumbar injection curcumin can suppress the generation of ischemia-reperfusion rat cerebral tissue malonaldehyde (MDA) and nitrite, improves superoxide dismutase (SOD) activity; (8) fibrosis: oral curcumin can obviously suppress Pulmonary Fibrosis in Rats due to bleomycin, reduces rat liver collagen deposition and spider cell DNA synthetic.In agarose gel, the extract of Rhizoma Curcumae Longae has protective effect to the oxidative damage of DNA; (9) relieving psychological pressure: oral Rhizoma Curcumae Longae ethanol extraction can reduce the pressure that the mandatory swimming of mice produces, and comprises levels such as reducing serotonin, 5-HIAA, norepinephrine, dopamine.The Oral Administration in Rats Rhizoma Curcumae Longae ethanol extraction of long-term slight pressurized, can increase interleukin 6 (IL-6), the tumor necrosis factor α (TNF-α) of serum, lowers the activity of the natural killer cell (NKC) of splenocyte, reaches the effect of decompression; (10) blood sugar lowering: oral blood glucose and the plasma glycoprotein that can reduce the type 2 diabetes mellitus mice of tetrahydrocurcumin.The oral blood glucose that can suppress type 2 diabetes mellitus mice KK-A (y) of curcuminoid in the turmeric ethanol extraction and the sesquiterpenoids composition in hexane extract rises.Curcumin is oral to diabetic nephropathy rats due to streptozotocin, can improve oxidative stress, produces the kidney protective effect; (11) on the impact of cardiovascular system: oral curcuma powder can reduce the myocardial cell apoptosis of myocardial ischaemia reperfusion injury rat, the myocardial infarction that minimizing is caused by ischemia-reperfusion, recover myocardium antioxidant status and the hemodynamic parameter of change, obviously reduce lipid peroxidation; (12) other: Rhizoma Curcumae Longae also has effects such as regulating immunity, anti-gastric-ulcer, antifertility; Curcumin also has anti-skin oxidative damage, kills the effects such as leishmania.
the Radix Paeoniae Alba(ranunculaceae plant Radix Paeoniae
paeonia lactiflorapall. dry root.Summer, Qiu Erji excavate, clean, remove end to end and radicula, put in boiling water after boiling after removing crust or peeling and boil again, dry) according to documents and materials, Radix Paeoniae Alba root contains the monoterpene glycosides composition: peoniflorin, benzoylpaeoniflorin, galloylpaeoniflorin, Hydroxy peoniflorin, albiflorin
r1, oxypaeoniflorin, Radix Paeoniae aglycon ketone, (Z)-(1S, 5R)-β-pinen-10-yl-
β-vicianoside, paeonilactones A, B, C, 6-O-β-D-glucnoxqanosyl-lactinolide; Three
ter penoids: 11 α, 12 α-epoxy-3 β, 23-dihydroxyolean-28,13 beta-ol ide, 3 β-hydroxy-11-
Oxo-olean-12-en-28-oic acid, 3 β, 23-dihydroxy-olean-11,13 (18)-dien-28-oic acid, 11 α, 12 α-epoxy-3 β, 23-dihydroxy-30-norolean-20 (29)-en-28,13 beta-ol ide; Also contain
canhydrolyzable tannin: 1,2,3,4,6-five galloyl glucoses, cachou extract [(+)-catechin], 1,2,3,4-tetragalloyl
-6-digalloyl-β-D-glucose etc.; Volatile oil is mainly containing benzoic acid, paeonol etc.
Radix Paeoniae Alba bitter in the mouth, acid, cold nature.Return liver, spleen channel.There is nourishing blood for regulating menstruation, astringing YIN to stop sweating, easing the affected liver to relieve pain, suppressing liver-YANG.For blood deficiency and yellow complexion, menoxenia, spontaneous perspiration, night sweat, hypochondriac pain, stomachache, limb pain twin, have a headache dizzy.The modern pharmacological research data shows, the Radix Paeoniae Alba has following pharmacological action: (1) spasmolytic: Radix Paeoniae Alba water extraction liquid has obvious inhibitory action to rabbit intestinal tube smooth muscle movement.To the next day stomach electricity arhythmicity rat of fasting due to feeding, Radix Paeoniae Alba decoct can be by neurally reducing nitrogen and cholinergic nerve increases and make its stomach electricity rhythm and pace of moving things recover normally.Radix Paeoniae Alba water extraction liquid has obvious inhibitory action to the contraction frequency in isolated mouse uterus due to oxytocin; (2) analgesia: confirm that with hot plate method in mice, writhing method Radix Paeoniae Alba total glucosides has analgesic activity, can obviously extend mice and shout incubation period, suppress writhing response; Its analgesic activity is not overturn by naloxone; (3) immunoloregulation function: with Radix Paeoniae Alba water decoction, to mice, feed, phagocytic percentage and the phagocytic index of Turnover of Mouse Peritoneal Macrophages all are significantly improved than matched group.Radix Paeoniae Alba total glucosides produces leukotriene B to rat peritoneal macrophages
4inhibitory action with suitable with the NSAID (non-steroidal anti-inflammatory drug) flufenamic acid of dosage, and be dosage correlation, the antiinflammatory of prompting Radix Paeoniae Alba total glucosides and immunoregulation effect may with the leukotriene B of its impact
4generation relevant.All to adjuvant arthritis rats, low splenic lymphocytes has potentiation for Radix Paeoniae Alba total glucosides, peoniflorin and Radix Paeoniae Alba total glucosides removal peoniflorin, prevents that peritoneal macrophage from producing excessive interleukin-11 (IL-1); (4) protect the liver: D-Gal (D-Gal-N), bacillus calmette-guerin vaccine (BCG) are added to lipopolysaccharide (LPS), titanium tetrachloride and the various hepatic injury of albumin induced mice to Radix Paeoniae Alba total glucosides and Liver Fibrosis Model all has protective effect, can obviously reduce serum alanine transaminase (ALT) and aspartate transaminase (AST) level, alleviate pathological lesion and the fibrosis of liver; (5) antibiotic: the Radix Paeoniae Alba all has inhibitory action in various degree to staphylococcus aureus, Hemolytic streptococcus, Streptococcus viridans, streptococcus pneumoniae, Bacillus typhi, Bacillus paratyphosus B, escherichia coli, bacillus pyocyaneus; (6) on the impact of cardio-cerebrovascular: the rat platelet coagulation that Radix Paeoniae Alba total glucosides is induced adenosine diphosphate (ADP) (ADP) has inhibitory action; Can obviously improve the function of the rabbit ischemic myocardial that pituitrin causes, extend the time that asphyxiating hypoxia mice electrocardio disappears; Also can extend panting the time after the disconnected cranium of mice, improve the brain electrical acti of rat, reduce brain calcium, sodium and water content, cerebral infarction is plugged with to protective effect, the mechanism of action may and reduce apoptosis-related with free radical resisting; (7) other: the Radix Paeoniae Alba also has the effects such as antitumor, blood fat reducing, defying age, anti-stress and promotion learning and memory.
radix Glycyrrhizae(glycyrrhizic legume
glycyrrhiza uralensisfisch., Glycyrrhiza inflata Bat.
glycyrrhiza inflatabat. or Glycyrrhiza glabra L.
glycyrrhiza glabral. dry root and rhizome) according to documents and materials, Radix Glycyrrhizae root and rhizome master, containing take the triterpene saponin that pentacyclic triterpene is aglycon,, containing glycyrrhizin, is mainly potassium, the calcium salt of glycyrrhizic acid, is the sweet ingredient of Radix Glycyrrhizae; Preparing glycyrrhetinic acid after the glycyrrhizic acid hydrolysis, have another name called 18 β-glycyrrhizic acid; Other triterpene saponin has: Glycyrrhiza uralensis Fisch. saponin A, B, glyuranolide, uralenolide, glycyrrhizin A
3, B
2, C
2, D
3, E
2, F
3, G
2, H
2, J
2, K
2; Flavone compound has: 4',7-Dihydroxyflavanone, liquirtin, isoliquiritin unit, isoliquiritin, Neoliquiritin, Neoisoliquiritin, licoricidin (+)-Licoricidin., Licoricone, formononetin, different ononin, Licurazid, 5-O-methyl licoricidin (+)-Licoricidin., glycyrrhizin-4`-celery glycosyl (1 → 2) glucoside, glycyrrhizin-7,4`-diglucoside.
The Radix Glycyrrhizae sweet in the mouth, property is flat.GUIXIN, lung, spleen, stomach warp.There is invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, alleviate pain relieving, coordinating the actions of various ingredients in a prescription.For weakness of the spleen and stomach, fatigue and weakness, shortness of breath and palpitation, cough with copious phlegm, gastral cavity abdomen, the anxious pain of extremity contraction, carbuncle sore tumefacting virus, cushion toxicity, strong.The modern pharmacological research data shows, Radix Glycyrrhizae has following pharmacological action: the effect of (1) adrenocortical hormone sample: the glycyrrhizic acid in Radix Glycyrrhizae and preparation thereof and enoxolone can suppress kidney 11-β hydroxyl steroid dehydrogenase (11-OHSD) activity, make the local hydrocortisone of kidney or Corticosterone Level increase and then act on aldosterone receptor and produce the effect of mineralocorticoid sample over the aldosterone level.Also has in addition the effect of glucocorticoid sample; (2) on the impact of digestive system: bismuth glycyrrhetate potassium gavage Dichlorodiphenyl Acetate, water logging stress reach the rat gastric ulcer that pylorus ligation causes all good inhibitory action, but gastric acid secretion inhibiting also reduces pepsic activity.The Licorice root gavage has inhibitory action to rat stomach power, with it, causes that 5-hydroxy tryptamine (5-HT), P-material (SP) are relevant with vasoactive intestinal peptide (VIP) dyssecretosis; (3) antiinflammatory: the acute inflammation of oozing out inflammation and chronic granulation tissue hyperplasia that the mice auricle swelling that the Licorice root subcutaneous injection brings out Oleum Tiglii, acetic acid bring out all has obvious inhibitory action.Where main officer of Tibet is calculated may, owing to strengthening the Pituitary Adrenal s function, increase and the generation antiinflammatory action thereby adrenal hormone is secreted; Prostaglandin E in the effect of enoxolone and inflammation-inhibiting tissue
2(PGE
2) generation, antagonism inflammatory mediator histamine, 5-hydroxy tryptamine etc. relevant; (4) antibiotic, antiviral: experiment in vitro shows, Licorice root is to staphylococcus aureus, escherichia coli, Staphylococcus albus, group B streptococcus, Pseudomonas aeruginosa etc.; Licoflavone is to the staphylococcus aureus of methicillin-sensitivity, methicillin-resistant staphylococcus aureus, micrococcus luteus, pneumobacillus etc.; Monosodium glycyrrhetin all has significant inhibitory action to staphylococcus aureus, group B streptococcus, Streptococcus mutans etc.Glycyrrhizin has significant inhibitory action to I type herpes simplex virus (HSV-1), Severe acute respiratory syndrome (SARS) virus, cytomegalovirus and HIV (human immunodeficiency virus) (HIV); Licoflavone is 25 times of glycyrrhizin to the inhibitory action of HIV virus multiplication; Licorice root is to respiratory syncytial virus also inhibitory action; (5) on the impact of cardiovascular system: glycyrrhizin can make rat artery wall solvent body phospholipase A
2active obviously decline, also can suppress the inflammatory reaction of body and blood vessel wall, prevents arteriosclerotic generation and development.Quiver in the mice chamber that the anti-chloroform of this sour sodium lumbar injection energy of 18 β-Radix Glycyrrhizae brings out, chloroform-epinephrine caused rabbit ventricular arrhythmia, rat ventricular arrhythmia time of occurrence due to prolongation calcium chloride, rat and the Cor Leporis rule that slows down, the heart rate acceleration that part is resisted isoproterenol.In addition, licorice water extract, Radix Glycyrrhizae total flavones and isoliquiritigenin etc. also have antiarrhythmic effect; (6) relieving cough and expelling phlegm: licoflavone, enoxolone and Radix Glycyrrhizae extractum gavage mice ammonia is drawn cough, sulfur dioxide draws to cough that significant antitussive effect is all arranged, what wherein effect was the strongest is enoxolone.The antitussive of liquorice flavonoids compound is all relevant with maincenter and peripheral action.In addition, can also promote throat and bronchial analysis, present the effect of relieving cough and expelling phlegm; (7) removing toxic substances: Radix Glycyrrhizae and preparation thereof are poisoning to some drugs, alimentary toxicosis, interior metabolism product are poisoning certain Detoxication.Mechanism and the glycyrrhizic acid of removing toxic substances with poisonous substance in conjunction be converted into minuent or innocuous substance, glycyrrhizin absorption poisonous substance and epinephrine effect, with and hydrolysis after the enoxolone of generation and glucuronic acid to protect the liver function relevant; (8) antitumor: glycyrrhizin, glycyrrhizic acid, enoxolone etc. have antitumor action in various degree, and its mechanism is relevant with inducing apoptosis of tumour cell, antioxidation, anti-promoting, anti-mutation and immunoregulation effect; (9) other: Radix Glycyrrhizae also has the effects such as antioxidation, antiallergic, raising internal ear auditory function, anti-cerebral ischemia.
(2) the basic technology route determines
We are Chinese medicine compound, with hard capsule, are applied to clinical.According to traditional medication custom, adopt the concentrated method of water boiling and extraction to prepare capsule, beat powder because gained water extraction immersion cream is dry after hygroscopicity strong, be difficult for long preservation, screen by moulding process, add microcrystalline Cellulose can improve powder fluidity as adjuvant, and reduce the extractum hygroscopicity.Said preparation basic technology route is: it is concentrated that above nine flavor medical materials (Radix Notoginseng beats except powder) decoct with water extractions → water extraction liquid, dry must extract powder → add Radix Notoginseng powder and appropriate amount of auxiliary materials, mix homogeneously → filled capsules → polishing → bottling, finished product.
two, medical material pre-treating technology research
Scald Rhizoma Cibotii, Zaocys, Rhizoma Homalomenae, Rhizoma Curcumae Longae, the Radix Paeoniae Alba, Caulis Sinomenii, Radix Glycyrrhizae, Radix Notoginseng for " 2010 editions one one of Chinese pharmacopoeia is recorded product; Heiguteng exract is " Guizhou Province's Chinese crude drug, ethnic drug quality standard (version in 2003) ", and the prescription Chinese crude drug is identified by Korea Spro of No. 2 Affiliated Hospital of Guiyang College of Traditional Chinese Medicine rosy clouds associate professor of pharmacy.
scald Rhizoma Cibotiithis product is Dicksoniaceae plant Rhizoma Cibotii
cibotium barometz(L.) dry rhizome of J. Sm., remove silt, removes hard root, petiole and golden yellow fine hair, cuts sheet, and drying is scalded method according to appendix II D of Chinese Pharmacopoeia version in 2010 again, with stir-baking in sand, to heaving, removes remaining fine hair after cooling.
zaocysthis product is Colubridae animal Zaocys
zaocys dhumnades(Cantor) dry body.
rhizoma Homalomenaethis product is the aroid Rhizoma Homalomenae
homalomena occulta(Lour.) dry rhizome of Schoot, two seasons of spring and autumn excavate, and clean, and remove crust, dry.
heiguteng exractthis product is asclepiadaceae plant Caulis et Radix Periplocae Forrestii
periploca forrestii Schltr.dry root.
caulis Sinomeniithis product is the menispermaceous plants Sinomenium acutum
sinomenium acutum(Thunb.) Rehd. et Wils. and hair Sinomenium acutum
s. acutum(Thunb.) Rehd. et Wils. var.
cinereumrehd. the dry rattan of et Wils..Time of the year when autumn changes into winter taps, and binding or cut long section is dried.
radix Notoginsengthis product is panax araliaceae plant
panax notoginseng(Burk.) dry root of F. H. Chen and rhizome.Excavate before the flowers are in blossom autumn, cleans, and separates main root, supporting root and rhizome, drying.
rhizoma Curcumae Longaethis product is zingiberaceous plant
curcuma longal. dry rhizome.Excavate when stem and leaf is withered winter, cleans, and boils or steam to the saturating heart, dries, and goes out fibrous root.
the Radix Paeoniae Albathis product is the ranunculaceae plant Radix Paeoniae
paeonia lactiflorapall. dry root.Summer, Qiu Erji excavate, and clean, and remove end to end and radicula, put in boiling water after boiling after removing crust or peeling and boil, dry.
radix Glycyrrhizaethis product is glycyrrhizic legume
glycyrrhiza uralensisfisch., Glycyrrhiza inflata Bat.
g. in-
flatabat. or Glycyrrhiza glabra L.
g. glabral. dry root and rhizome.
three, the screening of process conditions
(1) Study on extraction
The mensuration of 1 medical material water absorption rate
Take 1/5 recipe quantity medical material (except Radix Notoginseng powder) and amount to 27g, add 10 times of water gagings and soak, soak different time, filter, claim wet medicine weight (till no longer increasing to medical material weight), measure the medical material water absorption rate, formula following (the results are shown in Table 1-1).
mbquality (g) under-medical material water suction saturation
mgthe quality (g) of-medical material under drying regime
From table 1-1, the medical material water absorption rate is 128.15%, for convenience of operation, take water absorption rate as 130% calculating, and the medical material water absorption is heavy 1.3 times of medical material.Therefore should add first the water of 1.3 times of amounts during water extraction.
The quadrature factor of 2 decocting processes
Under the condition that meets the medical material water absorption rate, soak 1h, investigate the principal element of amount of water, decocting time, three impact decoction effects of decoction number of times, by each factor 3 level, use L
9(3
4) orthogonal table arrangement test (table 2-1).Boiled process adopts orthogonal test to be screened (table 2-2), take the total solid matters yield as investigating index, and extraction process is inquired into.Quadrature variance analysis as a result and factor level analysis in table 2-3, table 2-4.
2.1 test method and result
2.1.1 sample preparation
Take 1/5 recipe quantity medical material (except Radix Notoginseng powder) 27g, by orthogonal test table, tested (table 2-2) (soaking for the first time 1h), medicinal liquid filters, the concentrated 100ml that is settled to.Standby.
2.1.2 the total solid matters yield is measured
From above-mentioned filtrate, each precision is got two parts of 10ml, and to the evaporating dish of constant weight, water bath method, measure according to dry weightless mensuration (" appendix IX G of Chinese pharmacopoeia version in 2010), calculates the total solid matters yield, and formula is as follows.
wfor the weight of solids in 10ml filtrate,
vfor constant volume,
wtfor the sample weight that feeds intake.
2.2 interpretation of result
Take the total solid matters yield as index, and analyze and can obtain from table 2-3, table 2-4: factor B has statistical significance, is principal element, and factor A, C affect without significance, is secondary cause.With reference to the mean estimated value of B factor level, this test index total solid matters yield height is better, therefore selects B factor level 3; For secondary cause A, B, select A level 1 according to cost-saving and need of production, C level 1, this prescription extraction optimum process condition is: A
1b
3c
1, medical material soaks 1 h, and 8 times of water gagings decoct 3 times (adding for the first time 1.3 times of water gagings), each 0.5 hour.
2.3 the process certification of three batch samples experiment
Get the medical materials such as boiling hot Rhizoma Cibotii, Zaocys, Rhizoma Homalomenae, Heiguteng exract, press optimal extract process A
1b
3c
1extract, measure the total solid matters yield, result shows (in Table 2-5): total solid matters yield meansigma methods is 14.43%, RSD=1.37%, illustrates that process stabilizing is feasible.
3 is concentrated and dry
3.1 the impact of extractum relative density on the extract dry time
Get medical material (except Radix Notoginseng) 1/5 recipe quantity 27 g such as boiling hot Rhizoma Cibotii, Zaocys, Rhizoma Homalomenae, Heiguteng exract, press optimal extract process A
1b
3c
1extract (soaking for the first time 1 h), collecting decoction, decocting liquid is statically placed in ambient temperature overnight, filters, the concentrated 100ml that is settled to.Standby.Precision measures the equivalent extracting solution, and, to different relative densities, in 80 ℃ of constant pressure and dries, time length sees drying concentrated (traditional handicraft is concentrated).The results are shown in Table 3-1.
Result of the test shows: when extractum is concentrated into relative density and is 1.35-1.40, dry shortest time used, and also easy operating, be 1.35-1.40 therefore select extractum is concentrated into to relative density.
3.2 the impact of baking temperature on the extract dry time
Get medical material (except Radix Notoginseng) 1/5 recipe quantity 27 g such as boiling hot Rhizoma Cibotii, Zaocys, Rhizoma Homalomenae, Heiguteng exract, press optimal extract process A
1b
3c
1extract (soaking for the first time 1 h), collecting decoction, decocting liquid is statically placed in ambient temperature overnight, filters, the concentrated 100ml that is settled to.Standby.Precision measures the equivalent extracting solution, and being concentrated into relative density is 1.35-1.40, with different temperatures, different drying mode (constant pressure and dry, drying under reduced pressure), is dried to constant weight, sees drying the time.In Table 3-2.
From table 4-2,80 ℃ of drying under reduced pressure (0.06 MPa) are consuming time few, and extractum is easy to pulverize; 80 ℃ of dryings of normal pressure are consuming time consuming time slightly long than 80 ℃ of drying under reduced pressure.When baking temperature is 90 ℃, because its excess Temperature likely causes the change of its effective ingredient, therefore do not adopt.Consider, select 80 ℃ of constant pressure and dry extractum.
(2) preparations shaping technical study
The preparation of 4 extract powders
Get the medical material of recipe quantity, according to the preferred technique of Golden Crow Jiangu capsule for strengthening bone Study on extraction extracted, concentrated, drying under reduced pressure processes to obtain dry extract.Dry extract is pulverized, and crosses 65 mesh sieves, gets dry extract and soaks powder, moistureproof standby.Different batches Golden Crow Jiangu capsule for strengthening bone Chinese crude drug (except Radix Notoginseng) paste-forming rate experimental data, in Table 4.
Result: by the experiment of 8 batches, its average paste-forming rate is 11.50%.
The selection of 5 adjuvants
5.1 prescription day dose is determined
According to former clinical prescription medical material amount (except Radix Notoginseng), being 135 g, is the dose on the three of being grown up, and the paste-forming rate by 11.50% calculates, it is 6.175 g that the adult takes extractum total amount (containing Radix Notoginseng) every day, draft day taking three to four times, each serving with 4 0# hard capsules, every fills 0.45 g.Substantially meet and former clinical prescription day take the crude drug amount.
5.2 the preparation of the former powder of medicine
According to clinical prescription dosage, this product paste-forming rate and finished product day taking dosage, the ratio of calculating preparation extract powder used and adjuvant is 3.38:1, press pertinent literature, it is adjuvant that seminar selects microcrystalline Cellulose, soluble starch, design 4 different prescriptions, study they and the moisture absorption situation (design is write out a prescription in Table 5-1) of the mixed medicated powder of extract powder and full extract powder.
5.2 the percentile mensuration of medicated powder moisture absorption
Weighing botle is dried to constant weight, and cooling accurately weigh afterwards, add respectively the fine drug powder after above-mentioned mixing, at about 2 mm of even stand, weighing botle bottom thickness, precise weighing.The exsiccator that separately bottom is filled to the NaCl supersaturated solution is put into 25 ℃ of incubator constant temperature 24 h, now, relative humidity in exsiccator is about 75%, powdered medicine bottle after weighing is put into to exsiccator (the weighing bottle cap is opened), respectively at 24,48,72,96h weighs, and is calculated as follows medicated powder moisture absorption percentage rate.
The 2 medicated powder moisture absorption percentage rate reductions of writing out a prescription show at most microcrystalline Cellulose anti humility performance optimum, therefore determine its adjuvant as this capsule.
5.3 the former powder physical characteristic of medicine is investigated
Prepare 1 batch of former powder of Golden Crow Jiangu capsule for strengthening bone by technique, measure critical relative humidity, stop than angle and bulk density, to investigate production process, to the ambient humidity requirement, the mobility of medicated powder and capsule loading amount.
5.3.1 the critical relative humidity of the former powder of medicine is measured
Hard capsule filling environment humidity is very large on hard capsule fill impact, is necessary to measure the critical relative humidity of the former powder of Golden Crow Jiangu capsule for strengthening bone.At the about former powder of 2 mm of the weighing botle bottom tiling thickness of constant weight, at P
2o
5in exsiccator, be placed to constant weight, prepare altogether 7 duplicate samples, be placed in respectively in the drying receptacle that fills variable concentrations sulphuric acid and different salt supersaturated solutions (the weighing bottle cap is opened), in 25 ℃ of constant incubators, keep weighing after 7 d, calculate former powder hydroscopicity, in Table 5-2.
6 packings
The sealing in medicinal high density polyethylene packaging bottle of packing into of populated capsule is preserved, investigate through preliminarily stabilised, room temperature (relative humidity is controlled at 62%) is lower preserves 13 months, and capsule still keeps neatly, without adhesion, is out of shape hardening, the phenomenon such as break.Content is without the moisture absorption, air slaking, stiff, the phenomenon such as spoiled of luming.
7 pilot scales
Carry out 10 times of productions of three batches of amplifications by working out preparation process condition, the production technology index is carried out to comprehensive assessment, medical material and finished product are carried out to performance rating, investigate this product preparation technology's reasonability.By data show in table 7, should produce 10000 finished products by fed intake theory, capsule finished product net yield is not less than 85%.The explained hereafter condition meets the large production requirement of factory, and operability is stronger, and finished product, medical material, semi-manufactured goods quality are controlled, and end product quality is stable.Pilot scale processing parameter and pilot product Quality Checkout Data, in Table 7.
table 7 pilot scale processing parameter and pilot product quality testing data
experiment two: clinical drug efficacy study
1 clinical data
1.1 the routine RA patient of physical data 90 is my institute's Rheumatism Dept. outpatient service and inpatient, by table of random number, carries out Unified number, is divided into two groups, treatment group 90 example and matched group 30 examples.Male 18 examples in treatment group 90 examples, female's 42 examples, 16~70 years old age, average 51.78 ± 14.67 years old; The course of disease is the longest 21 years, the shortest 6 months, and average 4.83 ± 5.14; The function of joint classification is formulated standard with reference to ACR
[1]: I level 22 examples, II level 14 examples, III level 10 examples, IV level 14 examples.Male 11 examples in matched group 30 examples, female's 19 examples, 16~69 years old age, average 50.71 ± 15.13 years old; The course of disease is the longest 19 years, the shortest 6 months, and average 5.44 ± 3.91; Function of joint classification I level 11 examples, II level 8 examples, III level 7 examples, IV level 4 examples.The clinical datas such as two groups of patient ages, sex, the state of an illness, function of joint distribute without significant difference (
p>0.05).
1.2 diagnostic criteria
The Western medicine diagnose standard, the RA criteria for classification of promulgating in 1987 by American Rheumatism Association
[2];
wrist, metacarpophalangeal joints or proximal interphalangeal joint are swollen, continue at least 6 weeks.
Possess more than 4 or 4 and can make a definite diagnosis rheumatoid arthritis in above 7.
The Syndrome Classification standard is pressed Ministry of Public Health " new Chinese medicine treatment rheumatoid arthritis guideline of clinical investigations ", and card belongs to the kidney qi asthenic cold type
[3].
Primary symptom: joint cold type of pain and swelling, pain increase in intensity under coldness, pain alleviated while getting warmth, the joint joint stuffiness, morning deadlock, joint deformity.
Inferior disease: tastelessness and no thirst, aversion to wind and cold, overcast and rainy increasing the weight of, limbs are heavy.
The tongue arteries and veins: pale tongue, tongue is white, a little less than deep-thready pulse.
1.3 inclusive criteria is the masculinity and femininity patient in age 16-70 year (1); (2) the criteria for classification and the tcm diagnosis standard that meet RA, card belongs to the kidney qi asthenic cold type; (3) with other impact, do not treat and detect the disease of index; (4) be willing to the therapist of being checked.(5) participated in the Informed Consent Form of this test by the agreement of patient or its family members (guardian) signature.
1.4 exclusion standard
?(1) except the regulation medication, long-term taking is treated Western medicine or the other drug person of not withdrawing of primary disease; (2) merge intentionally, the serious disease persons such as brain, liver, renal insufficiency and hemopoietic system; (3) the age is person below 16 years old or more than 70 years old; (4) gestation or women breast-feeding their children; (5) allergic constitution, or those who are allergic to this drug; (6) according to the judgement of researcher, think and should not those selected.
1.5 reject and the case rejecting case that comes off: (1) do not meet inclusive criteria and the person of being included into; (2) not medication in accordance with regulations, can't judge curative effect, or data not umbra ring curative effect or safety judgement person.The judgement come off: screen the qualified patient who enters test, all have the right to exit at any time clinical trial, no matter when what is because exiting, and as long as no completing, clinical trial is omnidistance to be observed, and is the case that comes off.Case management comes off: after the patient comes off, contact with the patient as far as possible, complete the evaluation item that can complete, record as far as possible last medicine time.To because untoward reaction comes off, whether relevant with trial drug through following up a case by regular visits to last judgement.
research method
2.1 Therapeutic Method treatment group: oral Golden Crow Jiangu capsule for strengthening bone (Drug Manufacturing Room of the court produce, lot number: 050203,051223), each 4, every day 3 times; Matched group: oral rheumatoid arthritis sheet [the good nurse's Pharmaceutical in Liaoning (group) Co., Ltd produces, lot number: 050306,060103], each 4, every day 3 times.Two groups for the treatment of times are 2 months.
2.2 observation item
(1) tcm symptom sign (in Table 1), clinical symptoms and function of joint: arthralgia or tenderness number, arthroncus number, stiff time in morning, the average grip of both hands; (2) lab testing: rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), C reactive protein (CRP); (3) safety detects: blood, urine, stool routine examination, hepatic and renal function, rabat, electrocardiogram etc.; (4)) x-ray is taken the photograph sheet: the positive bit slice in both hands joint, read sheet by the blind method of radiologist.
2.3 curative effect determinate standard is clinic control (1): cardinal symptom, the whole improvement rate of sign >=75%, erythrocyte sedimentation rate and c reactive protein normally or obviously improve or approach normal; (2) produce effects: cardinal symptom, the whole improvement rate of sign >=50%, erythrocyte sedimentation rate and c reactive protein are improved; (3) effective: the whole improvement rate of cardinal symptom, sign >=30%, erythrocyte sedimentation rate and c reactive protein are improved or without improvement; (4) invalid: cardinal symptom, the whole improvement rate of sign<30%, erythrocyte sedimentation rate and c reactive protein are without improvement.
Cardinal symptom, sign refer to the stiff time of arthralgia number, arthroncus number, morning (minute), 5 of pain level and function of joint classifications etc.Whole improvement rate refers to the percentage rate that improves of above 5 indexs: (before treatment-treatment is rear)/the front value for the treatment of * 100%, ask its meansigma methods after addition.
The tcm syndrome curative effect is concluded standard:
Clinic control: tcm clinical practice symptom, sign disappear, and the syndrome integration reduces >=95%.
Produce effects: tcm clinical practice symptom, sign are obviously improved, and the syndrome integration reduces >=70%.
Effectively: tcm clinical practice symptom, sign all are improved, and the syndrome integration reduces >=30%.
Invalid: tcm clinical practice symptom, sign all are not improved, even increase the weight of, the syndrome integration reduces not enough >=30%.
Computing formula (nimodipine method): [integration before integration after integration before treatment-treatment/treatment] * 100%.
2.4 statistical method
adopt the SPSS17.0 software analysis, the measurement data data are used
± S means, between two groups measurement data relatively with the t check, the enumeration data rate relatively use χ
2check, ranked data adopt Ridit to analyze.
2.5 effectiveness and safety evaluatio
(1) efficiency evaluation: detect respectively the curative effect index such as ESR, CRP, RF before treatment and after treatment, and carry out the semiotics scoring.(2) safety evaluatio: detect the safety indexes such as routine blood test, routine urinalysis, stool routine examination, hepatic and renal function before treatment and after treatment, carry out safety evaluation.
result
Statistics after 3.1 the treatment of case dropping situations case dropping situations finishes, treatment group, matched group are all without the case that comes off.
3.2 Clinical efficacy comparison treatment group clinic control 15 examples, produce effects 17 examples, effective 14 examples, invalid 14 examples, total effective rate is 76.7%; Matched group clinic control 4 examples, produce effects 7 examples, effective 8 examples, invalid 11 examples, total effective rate is 63.3%, two group relatively statistical significance (P<0.05).
3.3 before and after two groups of patient treatments traditional Chinese medical science disease integral contrast in Table 1, table 2, primary symptom, inferior disease all have clear improvement (P<0.05 or P<0.01) after two groups of patient treatments, except arthralgia and joint, do cold two diseases, all the other indices treatment groups all are better than matched group (P<0.05).
3.6 untoward reaction do not occur in the routine patient treatment process of safety evaluatio treatment group 60.In the routine patient treatment process of matched group 30, untoward reaction 4 examples (13.33%) appear, gastrointestinal reaction 2 examples wherein, transaminase's 1 example that slightly raises, menolipsis 1 example.Two groups of patients recover normally after anti symptom treatment, not impact treatment.
conclusion
RA belongs to motherland's medical science " arthromyodynia " category, "Nei Jing" has proposed the earliest wind-cold damp pathogen and body and " in outer, has been harmonious " and causes the viewpoint of numbness, think in " wet three gas of wind and cold mix to combined into numbness also ", point out that it occurs except the invasion and attack of the wet exopathogen of wind and cold, also relevant with the positive QI-insufficiency of body.Chinese medicine is treated the history that more than one thousand years is arranged to RA, remarkable because of clinical efficacy, toxic and side effects is little, day by day is subject to people's attention.Golden Crow Jiangu capsule for strengthening bone is that the Miao in Guizhou compatriot is used for the treatment of for a long time arthromyodynia one of experience side is arranged, and as inventor's prescription of reaching an agreement on, my institute's Rheumatism Dept. is used for the treatment of RA and has shown better clinical efficacy.Medicine scalds the compositions such as Rhizoma Cibotii, Caulis Sinomenii, Heiguteng exract, Rhizoma Homalomenae, Zaocys, Radix Notoginseng, the Radix Paeoniae Alba, Rhizoma Curcumae Longae, Radix Glycyrrhizae.The invigorating the liver and kidney of monarch drug Rhizoma Cibotii, strong spinal column, wind-damp dispelling, the Zaocys wind-damp dispelling, restore menstrual flow and invigorate blood circulation; Ministerial drug Rhizoma Homalomenae, Heiguteng exract, little cyanine Radix seu Caulis fici Martinii wind-expelling pain-stopping, strengthening the tendons and bones; Adjuvant drug Radix Notoginseng, Rhizoma Curcumae Longae promoting blood circulation and stopping pain; Make the medicine Radix Paeoniae Alba, the Radix Glycyrrhizae stomach function regulating that nourishes blood, relieving spasm to stop pain.Full side has the effect of reinforcing the kidney to strengthen the bone, promoting blood circulation, dredging meridian and relieving pain, make that muscles and bones is strong, loose through ruton, strongly fragrant heresy, blood stasis, heresy is moved back and is not just being hindered, from the kidney invigorating, strong muscle, strong bone, invigorate blood circulation, nourish blood, dispel the wind, the multi-angle prescriptions such as dredging collateral, analgesic therapy, shape is loose and power is special, coordinates precise and appropriate.In the strong bone side of the clinical research confirmation Golden Crow in early stage, the treatment to RA has good efficacy for we, especially alleviate RA patient clinical symptom, reduce antirheumatic and shown clinical efficacy preferably as the toxic and side effects aspect of methotrexate etc., it is furtherd investigate, inquire into its treatment mechanism, improve treatment, the quality of making the life better of RA, there is wide potential applicability in clinical practice.Show that by this group data Golden Crow Jiangu capsule for strengthening bone is evident in efficacy to the RA patient clinical, can alleviate RA patient clinical sings and symptoms, reduce the inflammatory parameters such as erythrocyte sedimentation rate, c reactive protein, clinical efficacy is better than the rheumatoid arthritis sheet.
, model case
Left so-and-so, female, 42 years old, the grade teacher, (outpatient service number: 1180873) of going to a doctor in April, 2006.The patient extremity multi-joint symmetry pain occurred without obvious inducement before 3 years, being carrying out property increases the weight of, look into the RF positive in outer court, the anti-CCP positive, diagnosis RA, give the intravenous injection methotrexate, oral English is the treatments such as green grass or young crops, leflunomide, Glucosidorum Tripterygll Totorum too, it is not obvious that arthralgia is alleviated, and erythrocyte sedimentation rate, c reactive protein continue to raise, and turns to control that many hospital's curative effects are not good enough inside and outside the province.Both hands carpal joint and metacarpophalangeal joints are out of shape gradually, and doctor advised adds uses biological preparation, and the patient, because of the application of economic cause refusal, introduces by friend my section of going to a doctor.Look into: both hands metacarpophalangeal joints, proximal interphalangeal joint, carpal joint and double knee joint swelling, sharp ache, meet cold increasing the weight of, soreness of the waist and knees, the part joint deformity, moving obstacle, can't take care of oneself, and the X sheet shows both hands interphalangeal joint narrow gaps, the bone destruction of part joint, routine blood test shows HGB:81g/L, PLT:372 * 10
9/ L, ESR:102mm/h, CRP:86mg/L, RF:320IU/L.Pale tongue, tongue is greasy in vain, a little less than deep-thready pulse.Tcm diagnosis: arthromyodynia belongs to the kidney qi deficiency and coldness.Western medicine diagnose: rheumatoid arthritis.Reinforcing the kidney to strengthen the bone is given in Chinese traditional treatment, promoting blood circulation to remove obstruction in the collateral, oral Golden Crow Jiangu capsule for strengthening bone (medicine is comprised of boiling hot Rhizoma Cibotii, Zaocys, Rhizoma Homalomenae, Heiguteng exract, Caulis Sinomenii, Radix Notoginseng, Rhizoma Curcumae Longae, the Radix Paeoniae Alba, Radix Glycyrrhizae etc.), each 4, every day 3 times, arthralgia slightly subtracts, after taking January, the diet multiplication, arthralgia obviously alleviates.Continue and take 2 months, arthroncus disappears, and pain is not obvious, improving action, and the check routine blood test is normal, ESR:21mm/h, CRP:2.7mg/L.After continuing conditioning after treatment half a year, all diseases are eliminated substantially, and physical recovery is good.
The specific embodiment
embodiment 1:raw material: scald Rhizoma Cibotii 312.5g Zaocys 208.3g Rhizoma Homalomenae 312.5g
Heiguteng exract 187.5g Caulis Sinomenii 625.0g Radix Notoginseng 62.5g Rhizoma Curcumae Longae 416.7g Radix Paeoniae Alba 625.0g Radix Glycyrrhizae 125.0g microcrystalline Cellulose 85g
Preparation method: it is standby that Radix Notoginseng breaks into fine powder, the water soaking that all the other 8 flavor medicines add 9.3 times of amounts for the first time decocted 0.5 hour after 1 hour, the decocting that second and third time respectively adds 8 times of amounts boils, and each 0.5 hour, merges decocting liquid 3 times, filter, it is 1.35~1.40(60 ℃ that the filtrate normal pressure is concentrated into relative density) thick extractum, be placed in 80 ℃ of constant pressure and dries, broken mistake 65 mesh sieves of dried cream powder are mixed homogeneously with Radix Notoginseng powder, microcrystalline Cellulose, the 0# hard capsule of packing into makes 1000 of hard capsules, obtains Golden Crow Jiangu capsule for strengthening bone.
Usage and dosage: oral, 3 times on the one, each 4.
embodiment 2:raw material: scald Rhizoma Cibotii 200g Zaocys 100g Rhizoma Homalomenae 200g Heiguteng exract 150g Caulis Sinomenii 500g Radix Notoginseng 40g Rhizoma Curcumae Longae 300g Radix Paeoniae Alba 500g Radix Glycyrrhizae 80g microcrystalline Cellulose 60g
Preparation method: it is standby that Radix Notoginseng breaks into fine powder, the water soaking that all the other 8 flavor medicines add 9.3 times of amounts for the first time decocted 0.5 hour after 1 hour, the decocting that second and third time respectively adds 8 times of amounts boils, and each 0.5 hour, merges decocting liquid 3 times, filter, it is 1.35~1.40(60 ℃ that the filtrate normal pressure is concentrated into relative density) thick extractum, be placed in 80 ℃ of constant pressure and dries, broken mistake 65 mesh sieves of dried cream powder are mixed homogeneously with Radix Notoginseng powder, microcrystalline Cellulose, the 0# hard capsule of packing into makes hard capsule, obtains Golden Crow Jiangu capsule for strengthening bone.
Usage and dosage: oral, 3 times on the one, each 4.
embodiment 3:raw material: scald the Rhizoma Cibotii 400g Zaocys 300g Rhizoma Homalomenae 400g Heiguteng exract 350g Caulis Sinomenii 700g Radix Notoginseng 100g Rhizoma Curcumae Longae 500g Radix Paeoniae Alba 700 g Radix Glycyrrhizae 160g microcrystalline Cellulose 110g
Preparation method: it is standby that Radix Notoginseng breaks into fine powder, the water soaking that all the other 8 flavor medicines add 9.3 times of amounts for the first time decocted 0.5 hour after 1 hour, the decocting that second and third time respectively adds 8 times of amounts boils, and each 0.5 hour, merges decocting liquid 3 times, filter, it is 1.35~1.40(60 ℃ that the filtrate normal pressure is concentrated into relative density) thick extractum, be placed in 80 ℃ of constant pressure and dries, broken mistake 65 mesh sieves of dried cream powder are mixed homogeneously with Radix Notoginseng powder, microcrystalline Cellulose, the 0# hard capsule of packing into makes hard capsule, obtains Golden Crow Jiangu capsule for strengthening bone.
Usage and dosage: oral, 3 times on the one, each 4.
Claims (3)
1. a Chinese medicinal capsule for the treatment of rheumatoid arthritis, it is characterized in that: according to listed as parts by weight, it is to be prepared from by boiling hot Rhizoma Cibotii 200~400g, Zaocys 100~300g, Rhizoma Homalomenae 200~400g, Heiguteng exract 150~350g, Caulis Sinomenii 500~700g, Radix Notoginseng 40~100g, Rhizoma Curcumae Longae 300~500g, the Radix Paeoniae Alba 500~700g, Radix Glycyrrhizae 80~160g, microcrystalline Cellulose 60~110g.
2. treat according to claim 1 the Chinese medicinal capsule of rheumatoid arthritis, it is characterized in that: according to listed as parts by weight, it is to be prepared from by boiling hot Rhizoma Cibotii 312.5g, Zaocys 208.3g, Rhizoma Homalomenae 312.5g, Heiguteng exract 187.5g, Caulis Sinomenii 625.0g, Radix Notoginseng 62.5g, Rhizoma Curcumae Longae 416.7g, Radix Paeoniae Alba 625.0g, Radix Glycyrrhizae 125.0g, microcrystalline Cellulose 85g.
3. the preparation method of the Chinese medicinal capsule of the described treatment rheumatoid arthritis of claim 1 or 2, it is characterized in that: it is standby that Radix Notoginseng breaks into fine powder, the water soaking that all the other 8 flavor medicines add 9.3 times of amounts for the first time decocted 0.5 hour after 1 hour, the decocting that second and third time respectively adds 8 times of amounts boils, each 0.5 hour, merge 3 times decocting liquid, filter, the filtrate normal pressure is concentrated into the thick extractum that relative density is 1.35~1.40, be placed in 80 ℃ of constant pressure and dries, broken mistake 65 mesh sieves of dried cream powder are mixed homogeneously with Radix Notoginseng powder, microcrystalline Cellulose, the hard capsule and get final product of packing into.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310369119.1A CN103479963A (en) | 2013-08-22 | 2013-08-22 | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310369119.1A CN103479963A (en) | 2013-08-22 | 2013-08-22 | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103479963A true CN103479963A (en) | 2014-01-01 |
Family
ID=49820776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310369119.1A Pending CN103479963A (en) | 2013-08-22 | 2013-08-22 | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103479963A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104666461A (en) * | 2015-02-12 | 2015-06-03 | 贵阳中医学院 | Medicament for treating rheumatoid arthritis and preparation method of medicament |
CN104940478A (en) * | 2015-06-03 | 2015-09-30 | 贵阳中医学院第二附属医院 | Ginseng antler brain-nourishing prescription for treating AD diseases |
CN104940479A (en) * | 2015-06-03 | 2015-09-30 | 贵阳中医学院第二附属医院 | TCM composition for treating AD diseases |
CN105663624A (en) * | 2016-02-25 | 2016-06-15 | 太和县中医院 | Traditional Chinese medicinal capsules for dispelling wind and removing obstruction in the meridians and promoting Qi to activate blood |
CN107022553A (en) * | 2017-06-08 | 2017-08-08 | 扬州大学 | Chinese herbaceous peony HSP70 genes and its plant expression vector and application |
CN108653338A (en) * | 2018-07-12 | 2018-10-16 | 石河子大学 | Inhibit the active component production method and purposes of pathogenic entero becteria in nutgall |
-
2013
- 2013-08-22 CN CN201310369119.1A patent/CN103479963A/en active Pending
Non-Patent Citations (2)
Title |
---|
罗世江: "不同辅料对中药全浸膏制剂防潮效果探讨", 《中国医药导刊》 * |
龙小琴等: "苗药金乌健骨方治疗类风湿性关节炎(寒湿阻络证)30例临床观察", 《中医药导报》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104666461A (en) * | 2015-02-12 | 2015-06-03 | 贵阳中医学院 | Medicament for treating rheumatoid arthritis and preparation method of medicament |
CN104940478A (en) * | 2015-06-03 | 2015-09-30 | 贵阳中医学院第二附属医院 | Ginseng antler brain-nourishing prescription for treating AD diseases |
CN104940479A (en) * | 2015-06-03 | 2015-09-30 | 贵阳中医学院第二附属医院 | TCM composition for treating AD diseases |
CN105663624A (en) * | 2016-02-25 | 2016-06-15 | 太和县中医院 | Traditional Chinese medicinal capsules for dispelling wind and removing obstruction in the meridians and promoting Qi to activate blood |
CN107022553A (en) * | 2017-06-08 | 2017-08-08 | 扬州大学 | Chinese herbaceous peony HSP70 genes and its plant expression vector and application |
CN108653338A (en) * | 2018-07-12 | 2018-10-16 | 石河子大学 | Inhibit the active component production method and purposes of pathogenic entero becteria in nutgall |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yu et al. | Citri Reticulatae Pericarpium (Chenpi): Botany, ethnopharmacology, phytochemistry, and pharmacology of a frequently used traditional Chinese medicine | |
Yu et al. | Trichosanthis Fructus: botany, traditional uses, phytochemistry and pharmacology | |
CN101239112B (en) | Traditional Chinese medicine composition for regulating blood lipid and preparation method thereof | |
CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
KR102567235B1 (en) | Composition for the prevention and treatment of Inflammatory Bowl Disease | |
CN104940479A (en) | TCM composition for treating AD diseases | |
Li | Chinese herbal medicine | |
CN102145089B (en) | Traditional Chinese medicine for treating heart failure | |
CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
CN101342249B (en) | Chinese medicine formulations for treating hepatitis B and preparation method thereof | |
CN105267559A (en) | Diabetic peripheral neuropathy treatment medicine and manufacturing method thereof | |
CN102049010B (en) | Medicament for preventing and treating ischemic cerebrovascular diseases | |
CN104940513A (en) | Pharmaceutical composition for treating menopause syndrome | |
CN112057535B (en) | Preparation method of traditional Chinese medicine composition for preventing or/and treating dyslipidemia | |
CN105412898A (en) | Application of traditional Chinese medicine composition in preparing acute nephritis | |
CN108686157B (en) | Traditional Chinese medicine composition for preventing and treating blood stasis type nodules of breast, preparation method and pharmaceutical preparation thereof | |
CN106177712A (en) | A kind of magnificent Bulbus Allii bean treating cardiovascular and cerebrovascular disease and preparation method thereof | |
KR100760386B1 (en) | A composition for the prevention and treatment of arthritis, including the extract of the mixed herbal herbal medicine | |
CN112057536B (en) | Traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof | |
CN103768454A (en) | Composition for preventing and treating HIV/AIDS (Human Immunodeficiency Virus/ Acquired Immune Deficiency Syndrome) and preparation method thereof | |
CN103933386A (en) | Compound hemophiliac capsule used for treating hemophilia and preparation method thereof | |
KR20060030575A (en) | Pharmaceutical composition for the prevention and treatment of hyperthyroidism containing herbal extract | |
CN112089783B (en) | Application of traditional Chinese medicine composition in the preparation of medicine for preventing or/and treating obesity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140101 |